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ABSTRAK 
Pengenalan: Kajian telah menunjukkan secara konsisten bahawa pesakit dengan 
skizofrenia merokok pada kadar yang lebih tinggi dibandingkan dengan populasi umum. 
Kebergantungan nikotin, jenis kebergantungan substans paling kerap di kalangan pesakit 
skizofrenia, akan meningkatkan morbidity dan mortality kumpulan pesakit ini. Sehingga 
kini, tiada data tempatan berkaitan merokok dan kebergantungan nikotin di kalangan 
pesakit skizofrenia dapat diperolehi.  
Objektif: Kajian ini bertujuan untuk menentukan prevalens merokok dan 
kebergantungan nikotin di kalangan sebuah sampel pesakit luar dengan diagnosis 
skizofrenia, factor-faktor yang berkaitan dengannya dan keterukan penyakit di dalam 
sampel ini.  
Metodologi: Ini merupakan sebuah kajian keratan rentas seramai 181 orang pesakit 
dengan diagnosa skizofrenia di sebuah klinik pesakit luar psikiatrik sebuah hospital 
negeri. Diagnosa pesakit telah dipastikan menggunakan M.I.N.I. Pesakit yang memenuhi 
kriteria kajian kemudiannya dinilai tahap keterukan penyakit menggunakan PANSS. 
Pesakit yang merokok diminta untuk memenuhkan FTND. Kesemua peserta kajian 
kemudian diuji tahap karbon monoksida dalam udara yang dihembus menggunakan 
sebuah alat yang boleh dipegang di tangan.  
Keputusan: Prevalens perokok di dalam sampel kajian adalah 38.1% dan 73.9% 
daripada mereka bergantung kepada nikotin. Perokok dikaitkan dengan jantina lelaki (OR 
62.36, p<0.01), Melayu (OR 3.03, p<0.05), pendapatan bulanan lebih daripada RM500 
(OR 0.43, p<0.01) dan menggunakan dadah ataupun alcohol (OR 12.96, p<0.01). Walau 
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bagaimanapun, faktor-faktor yang sama tiada kaitan dengan kebergantungan nikotin. 
Tiada kaitan didapati di antara skor FTND dan skor PANSS. 
Kesimpulan: Prevalens merokok dan kebergantungan nikotin adalah amat signifikan. Ia 
dapat dikaitkan dengan pendapatan bulanan yang lebih tinggi. Perkhidmatan yang khusus 
adalah wajar untuk menangani isu ini. Di masa hadapan, kajian tempatan yang dijalankan 
dalam bidang ini amatlah perlu bagi mengenalpasti fakto-faktor lain yang berkaitan 
dengannya. 
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ABSTRACT 
Introduction: Studies have consistently shown that people with schizophrenia smoke at 
higher rates than the general population. Nicotine dependence, the commonest substance 
use disorder in patients with schizophrenia would increase the morbidity and mortality in 
this group of patients. To date, there have been no local data pertaining to smoking and 
nicotine dependence in patients with schizophrenia.  
Objective: This study aimed to determine the prevalence of smoking and nicotine 
dependence in a sample of outpatients with schizophrenia, factors associated with it and 
the severity of disease in the study sample.  
Methods: This was a cross-sectional study of 181 patients with a diagnosis of 
schizophrenia in the outpatient psychiatric clinic of a state hospital. Diagnosis was 
confirmed using the M.I.N.I. Patients who met the inclusion criteria was then assessed for 
the severity of disease using PANSS. Smokers were given the FTND to complete. All 
study participants were tested using a handheld device meant to measure carbon 
monoxide levels in the expired air. 
Results: The prevalence of smokers in was 38.1% and 73.9% of them were nicotine-
dependent. Being male (OR 62.36, p<0.01), Malay (OR 3.03, p<0.05), earning more than 
RM500 a month (OR 0.43, p<0.01) and concomitant drug and alcohol abuse (OR 12.96, 
p<0.01) was significantly associated with smoking but not to nicotine dependence. No 
association was found between FTND scores and PANSS scores.  
Conclusion: The prevalence of smoking and nicotine dependence in our study sample 
was very significant. It was found to be associated with higher monthly earnings. 
xviii 
 
Nicotine dependence should be included into the management of patients with 
schizophrenia. Specialized services are warranted to deal with this issue. Future local 
studies in this field are needed to address and identify other associated factors. 
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PREVALENCE, ASSOCIATED FACTORS OF NICOTINE DEPENDENCE AND 
DISEASE SEVERITY IN PATIENTS WITH SCHIZOPHRENIA 
 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1 Schizophrenia and the burden of disease 
Schizophrenia is one of the most severe and disabling of mental illnesses and the 
consequences of a diagnosis of schizophrenia reaches beyond the individual(1). While the 
incidence of the disease is considered low, it is, however, a major contributor towards the 
global burden of disease. This burden is largely reflected in its two features: it has its 
onset in early adulthood which greatly impairs personal growth and productivity, and, 
secondly, two thirds of individuals with schizophrenia will still suffer from persistent or 
fluctuating symptoms despite them being on optimal medication.  
The World Health Organisation (WHO) Global Burden of Disease(2) reported 
that mental disorders, including schizophrenia, ranked among the 20 leading causes of 
disability.  In 2004, WHO estimated that 16.7 million people worldwide suffered from 
schizophrenia. The same report showed that in all regions, neuropsychiatric conditions 
were the most important causes of disability, accounting for 1.1% of the total DALYs 
(disability-adjusted life years) and 2.8% of YLDs (years lived with disability). Among 
males, schizophrenia ranked fifth and among females, sixth cause of YLD (3). 
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1.2 Epidemiology of schizophrenia 
Classically, the prevalence of schizophrenia has always been quoted as 1%(4). 
However, an analysis done by Saha and colleagues(5) have clearly disproved this to a 
lifetime prevalence of 4/1000 as opposed to the 1%. They also did not find any statistical 
difference in prevalence estimates between males and females. In addition, the 
prevalence was lower in developing nations and higher in migrants and in urban rather 
than rural settings.    
 
1.3 Symptomatology of schizophrenia 
The history of schizophrenia dates back to time immemorial. In his work in 1860, 
Morel used ‘démence-précoce’ to describe an early-onset state of bizarre behavior and 
abnormal mental function which begins in the young. Emil Kraepelin subsequently 
translated démence-précoce into dementia precox. Dementia precox better emphasized 
the disorder which involved changes in cognition (dementia) and its early onset (precox). 
Eugene Bleuler was the one who coined the term schizophrenia in 1911 to reflect the 
schisms between the thoughts, emotions and behavior present in patients with this 
disorder.  
According to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorder 
fourth edition)(6), the essential features are a mixture of positive and negative symptoms 
which have been present for a significant portion of time over the period of a month, with 
some signs persisting for at least 6 months. Positive symptoms infer an excess or 
distortion of normal functions. Positive symptoms may be exhibited by presentations of 
delusions, hallucinations, and disorganized speech and behavior, whereby, in DSM-IV, 
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the delusions and hallucinations are grouped into the psychotic dimension and 
disorganized speech and behavior into the disorganization dimension. Negative 
symptoms, which reflect dimunition or loss in normal functioning, include affective 
flattening, alogia and avolition. These negative symptoms might at time cloud the clinical 
picture and be taken for a depressive disorder instead.  
Schizophrenia is a disorder with a constellation of symptoms and no one symptom 
is considered pathognomonic. One of the other signs of the disorder is the presence of  
dysfunction in one or more areas of functioning. If the onset is in childhood or 
adolescence, the failure would most probably be seen in the form of not achieving what 
would have been expected of the individual. It could also be in the form of deterioration 
in function, whereby the person’s functioning is below that of what was achieved before 
the onset of the illness. 
A full blown picture of the disorder might not present itself at the onset but might 
be seen in the subthreshold forms of the afore-mentioned clinical symptoms. These might 
be either the positive or negative symptoms. These positive-like symptoms may present 
itself in the form of unusual beliefs but not of delusional proportions, vague perceptual 
experiences (e.g. sensing the presence of unseen persons), vague, digressive or overly 
abstract or concrete speech which might still be understandable or peculiar behavior 
which is not overtly disorganized. The negative symptoms may also mimic the afore-
mentioned depressive-like episode. 
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1.4 Brief history of smoking 
 Tobacco was initially cultivated and smoked in pipes by the Native Americans for 
medicinal and ceremonial purposes. Christopher Columbus was responsible for bringing 
tobacco leaves and seeds back with him to Europe but it was a French, Jean Nicot who 
popularized its use. Nicot was an adventurer and diplomat after whom nicotine was 
named(7).  
 Tobacco was first produced for pipe-smoking, chewing and snuff. It wasn’t until 
the early 1800s that cigars became popular. Cigarettes only became widely popular in the 
United States after the civil war even though crude forms of it have been available since 
the 1600s (7). 
 The early 20
th
 century saw a growing body of evidence which addressed the 
negative effects of smoking. Statistical correlation has been found between smoking and 
cancer. However, it wasn’t until an article published in the Reader’s Digest in 1952 titled 
“Cancer by the Carton” which detailed the dangers of smoking that the smoking public 
began to really sit up and take notice. This was further strengthened when the Surgeon 
General’s report on the effects of smoking on health was released in 1964. Since then, the 
tobacco industry has taken many hits but had managed to rise time and time again(7). 
 Since reports of the health hazards of smoking emerged, the tobacco industry has 
responded with various strategies to exert damage control. These include research into 
and production of cigarettes of various designs and tar contents. However, a more recent 
Surgeon General’s report published in 2010(8) clearly stated that there is no safe cigarette. 
Claims of filtered, low tar and “light” variations did not actually reduce risks of disease 
but had in fact impaired efforts at prevention and cessation. This is because introduction 
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of novel tobacco products might tempt first-time smokers and delay cessation in those 
who should have stopped altogether. Generally speaking, it would increase morbidity in 
the public.  
 
 
1.5 Substance use disorders (SUDs) in schizophrenia 
 The large Epidemiologic Catchment Area(ECA) (9) study found that nearly half 
of people with schizophrenia also present with a co-morbid diagnosis of substance abuse. 
The mechanisms underlying the high comorbidity between SUD and schizophrenia 
remains a poorly understood field. However, it is thought to likely include both common 
(across all drugs) as well as drug-specific (eg, nicotine and marijuana) factors(10).  
 Among those with a mental disorder, the odds ratio of having some substance use 
disorder was 2.7, with a lifetime prevalence of about 29%.(9) The highest substance use 
disorder comorbidity rate was found for those with drug (other than alcohol) disorders, 
53% of whom were found to have a mental disorder. It was also discovered that 
individuals treated in specialty mental health and substance use disorder clinical settings 
have significantly higher odds of having comorbid disorders. Among the institutional 
settings, comorbidity of substance use disorders and severe mental disorders was highest 
with antisocial personality, schizophrenia, and bipolar disorders. This was especially so 
in the prison settings. 
 Substance-using schizophrenia patients were more likely to be younger and male 
than nonusers. Substance users had significantly more hospitalizations and more 
outpatient visits with positive symptoms. There was a higher rate of missed appointments 
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in the substance-using patients, and it correlated with hospitalizations. Substance abusers 
had notably more negative symptoms, except in those cases for which the alcohol user 
required treatment for alcoholism. Current drug use also correlated with higher tardive 
dyskinesia scores, higher incidence of cognitive deficiency, less education, and higher 
average neuroleptic dose than with non-abusers or alcohol use(11). 
 The local National Mental Health Registry’s report between 2003-2005 found that 
20% of the patients with schizophrenia had a comorbidity, with substance abuse being the 
commonest at 80%. Cannabis was found to be the commonest substance of abuse. 
However, the report did not take into account the use of nicotine in this population. 
 Nicotine is by far the commonest abused substance by patients with 
schizophrenia. In may be due, in part to its status as a licit drug and also due to its easy 
availability(12).  
 
 
1.6 Smoking and Nicotine Dependence in Schizophrenia 
Smoking remains to be the single greatest preventable cause for morbidity and 
mortality worldwide. The health consequences that arise from smoking are well-
established and well-known to smokers but often taken lightly. 
Many studies have consistently proven that smoking and nicotine dependence are 
highly prevalent in patients with psychiatric illnesses in general. When compared across 
the diagnoses, patients with schizophrenia was found to have the highest number of 
smokers. When compared with the general population, patients with schizophrenia were 
almost twice as likely to smoke(13).  
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Patients with schizophrenia have been found to smoke heavier, smoked cigarettes 
with higher tar content and smoked for longer periods. Lohr and Flynn(14) have also 
highlighted that these patients preferred to smoke the cigarettes until the very end, 
leaving evidence of this in the yellow stains frequently found on the fingers of avid 
smokers. This was especially seen in the institutions and with chronic mentally ill 
patients. The behavior of letting cigarettes burn till the end is reinforced by the finding 
that nicotine levels are highest at the end of these cigarettes(15). 
A  meta-analysis of worldwide studies of schizophrenia and tobacco smoking 
behaviours(16) found that the prevalence of current smoking among patients with 
schizophrenia was 62%. This association was consistent among the 42 samples in 20 
nations included in the meta-analysis. It also found a world average odds ratio of 5.3 for 
current smoking in this group of patients when compared with the general population. 
This meta-analysis involved studies with both inpatient and outpatient samples. 
Hughes et al’s study(13) conducted among psychiatric outpatients found that the 
prevalence of smoking among the 277 subjects was 52% with the highest numbers found 
in patients with schizophrenia(88%) and mania (70%). This was also supported by 
another study performed in an outpatient clinic of an urban mental health center(17) 
which found that 74% of the 78 subjects with schizophrenia were current smokers. 
A Singaporean study done among Chinese patients with schizophrenia who 
smoked(18) found a relatively high rate of smoking (31.8%) compared to a rate  of  16% 
in the whole  of  the Chinese population in  Singapore. However, the rate described 
contrasted sharply with the higher rates found in Western studies due to vigorous anti-
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smoking campaigns mounted by the Singaporean authorities. There were also laws 
enacted in Sinagapore that made smoking illegal for people under 18 years of age.  
A study conducted in Japan on 172 patients with schizophrenia found that 40.7% 
of them smoked. This study involved inpatients in a suburban psychiatric hospital in 
Tokyo. The hospital had a smoking room on each floor where the patients were allowed 
to smoke, but only ready-made cigarettes(19). Although the prevalence was lower than a 
previously done study in Japan, it was still consistent with other earlier studies that 
reported extraordinarily high prevalences of smoking in schizophrenia patients (13, 17, 
20).  
Although no difference was found  between psychiatrically ill smokers and non-
smokers with regards to socioeconomic status and gender composition(16), in the general 
population smoking is more prevalent among men and in the lower socioeconomic strata. 
Several factors that have been found to be related to smoking behaviour in patients with 
schizophrenia include male sex, youth or old age, polydipsia, early onset, high number of 
previous hospitalisations and high doses of antipsychotic medications(17, 21). 
 Researches into smoking have now turned instead to nicotine dependence, as 
nicotine has been found to be the most addictive substance found in tobacco. In most 
cases, addiction to nicotine drives people to smoke everyday in order to avoid unpleasant 
withdrawal symptoms. DSM-IV’s core criteria for a mental disorder states : ‘clinically 
significant behavioural or psychological syndrome or pattern that occurs in an individual 
and associated with distress, disability and a significantly increased risk of suffering 
death and disability’(4). Therefore, nicotine dependence fulfills this criteria. Low rates of 
remission associated with nicotine dependence is very low, cited as less than 2-3% per 
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year in the United Kingdom(22). It has been considered the most prevalent mental 
disorder and would usually last for decades once dependence has been established. 
Even though literature on smoking is easily obtained, few had actually been on 
studies of the prevalence of nicotine dependence. Only for the past few years have 
research turned from smoking to nicotine dependence(23). Most large epidemiologic 
studies on drug or substance dependence had excluded nicotine dependence. The 
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) (24), for 
instance, which was conducted in the United States examined nicotine dependence and 
psychiatric disorders but did not explore nicotine dependence in patients with psychotic 
disorders.  
DSM  measures for nicotine dependence had not beeen as widely used as 
compared to non-DSM measures in the field of tobacco research(25). DSM focused more 
on impaired control over drug use and physical dependence. Several other instruments, 
for example the Fagerstrom Test for Nicotine Dependence (FTND) also studied amount 
of cigarettes used and craving. The DSM measures had also undergone much lesser tests 
of validation as compared to the non-DSM measures(25).  
 Several studies which used the FTND had classified nicotine-dependent patients 
as being mildly dependent, highly dependent and very highly dependent(26, 27). 
However, for the purpose of prevalence studies, a dichotomous definition would be more 
appropriate as it allowed the use of logistics regression to compare patients with 
schizophrenia who are nicotine dependent with a control group(16). Patkar et al(28) and 
Solty et al(29) both used the FTND to find the prevalence of nicotine dependence in their 
group of patients with schizophrenia. Both these studies dichotomized their patients into 
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dependent and non-dependent smokers. However, their study was conducted in the 
inpatient setting and found a prevalence of 75.9% and 47.5% each.  
 In the past, the success of tobacco control programs were based only on changes 
in smoking prevalences(30). A study done by Breslau et al (23) which was published in 
2001, found that there was a decline in the prevalence of daily smoking in persons aged 
18 to 24 years old during the period studied. However, the numbers needed a more 
careful perusal where nicotine dependence was concerned. The same study found that the 
prevalence of nicotine dependence among the young daily smokers increased at a higher 
rate than the decline in the prevalence of smokers among the young adults. This study 
proved that examining smoking alone was not sufficient without taking nicotine 
dependence into consideration. In can be inferred that by ignoring dependence, wrong 
conclusions may be drawn. More importantly, the problem of nicotine dependence would 
not be recognized in those group of people who needed it most(31).  
  In a study which compared nicotine dependence in patients with schizophrenia 
versus mood disorders, it was found that the odds of a patient having a high nicotine 
dependence was 2.8 times higher than controls(32).   The same study found that the odds 
ratio for a patient with schizophrenia to have high nicotine dependence was 2.6 as 
compared to controls and 3.3 for mood disorders. Gurpegui et al. (33) found a higher 
prevalence of high nicotine dependence in schizophrenia outpatient smokers when 
compared with voluntary controls who smoked . Within the same schizophrenia sample, 
high FTND (Fagerstrom Test For Nicotine Dependence) scores were associated with 
poor outcome of schizophrenia (27). 
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 Patients with schizophrenia who smoked also smoked heavier than the general 
population. Most studies defined heavy smoking as smoking at least 30 sticks or 1.5 
packs of cigarettes per day (16). Cigarettes are considered very effective tools which 
delivered nicotine to the brain. To avoid withdrawal symptoms patients associate with 
nicotine withdrawal, they tend to keep the number of cigarettes smoked in a day at a 
constant number. Therefore the number of cigarettes smoked in a day can be considered 
as a gross and stable indicator of smoking severity and nicotine dependence.  This was 
reflected in a study conducted in Nithsdale, Scotland(34) that found 68% of patients in 
their sample, compared with 11% found in general population samples,  smoked at least 
25 cigarettes per day. 
 Studies have also found low cessation rates in people with schizophrenia. When 6 
studies from 5 countries were combined, it was suggested that smoking cessation rates 
were smaller in patients with schizophrenia, at 9% versus between 14% and 49% for the 
general population (16). 
 Schizophrenia patients also initiated smoking at the same rate as when they were 
in their teens (32) even after they were 20 yrs of age while, in the control population, 
smoking initiation had decreased. This is in line with the hypothesis that some people 
who are vulnerable to schizophrenia became smokers later on in their 20s when other 
people rarely initiate smoking. Several studies have also reported that the proportion of 
patients who started smoking before the onset of illness was relatively high, ranging 
between 49-90%(16). A smaller study of first-episode psychosis patients also suggested 
that most patients with schizophrenia who smoked started doing so prior to the onset of 
illness(35). 
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1.7 Smoking and mortality risks in patients with schizophrenia 
A World Health Organization report published in 2009(36) on global health risks 
identified 24 mortality risk factors. The six leading risks, in order of priority were high 
blood pressure, tobacco use, high blood glucose, physical inactivity, overweight and 
obesity and high levels of cholesterol. These factors combined were responsible for 
increasing the risk for chronic disease and were accountable for 42.1% of global 
mortality. However, there were variations with regards to the importance of these risk 
factors across countries and income groups. Therefore, an understanding of the role that 
these risks play is important when planning strategies to improve global health.  
 The association between severe mental illness and increased rates of mortality is a 
fact of great concern and, in fact, long recognized and scrutinized. Since early 20
th
 
century, the increase in mortality rates, more specifically in the group of disorders now 
labeled as schizophrenia have been under examination. Kilbourne et al (37) reported that 
in economically developed countries, people with schizophrenia died 20-25 years 
prematurely. Cancer, respiratory disease, heart disease and digestive disease are the main 
perpetrators of the reduction in life span (38). These causes are actually similar as those 
seen in the general population. 
 The increasing number of studies which addressed mortality rates in people with 
schizophrenia has enabled the calculation of standardized mortality ratio (SMR) due to 
the availability of data for the general population. SMRs are calculated by dividing the 
observed mortality rates in a given population (eg number of deaths in a group of 
individuals with schizophrenia) by the expected mortality rates in that same group as 
predicted by age- and sex-specific mortality rates for a standard population(39). It was 
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found that the relative mortality risks associated with schizophrenia was on the rise and 
that the SMRs which was examined over the past 3 decades also increased in a linear 
fashion(39). This indicated that even though there was increased awareness and detection 
of psychotic disorders and more specifically schizophrenia, certain areas of care still 
needed to be developed and addressed. This included the evaluation and management of 
smoking and nicotine dependence. The same systematic review found that even though 
suicide contributed to the increased mortality associated with schizophrenia, the 
increased rates is also attributed to other numerous somatic conditions. 
 The WHO report (36) highlighted that smoking and tobacco to be the second most 
important global risk factor, the top being hypertension. According to the report, tobacco 
accounted for 8.7% deaths globally. As mentioned before, several studies (36, 38) 
consistently showed that the rates of smoking is 2-3 times more than the general 
population. More alarmingly, it has also been found that for patients with schizophrenia 
aged 34-54 years old, the odds for a cardiovascular-related death in smokers was 12 times 
increased as compared to non-smokers(40). A meta-analysis conducted by Catts et al (41) 
found that the incidence of lung cancer in patients with schizophrenia was significantly 
higher than in the general population. However, after adjusting for smoking prevalence, 
this significance diminished, which suggested that smoking was the main factor 
explaining the high prevalence of lung cancer in patients with schizophrenia. The rate of 
cancer deaths in schizophrenia smokers was also approximately doubled(42),which again 
indicated that the hazardous effects of smoking cannot be pushed aside.   
               As was mentioned before, schizophrenia is a debilitating illness  that exerts 
many biological, psychological and social effects on patients. Being also nicotine 
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dependent may increase morbidity further due to its effects on the various organ systems, 
mainly cardiovascular and pulmonary.  
 
1.8 Neurobiology and Pharmacology of nicotine 
 Nicotine is known to affect cognition and behavior. Cigarette smoke contains 
more than 7,000 chemicals and compounds(43). Hundreds are toxic and at least 69 cause 
cancer. Tobacco smoke itself is a known human carcinogen. Nicotine, however, remains 
as the most addictive. There have been many reports on the effects of nicotine and 
variations regarding individual responses to nicotine. However, not all individuals who 
have a history of exposure to nicotine will get addicted to it, therefore raising the question 
and the possibility that response and dependence on nicotine might be genetically 
determined(44).  
Tobacco has long been considered the most widely used method for the delivery 
of nicotine and therefore, the most addictive. Upon inhalation of cigarette smoke, 
nicotine is rapidly absorbed into the circulation and act on almost all physiological 
systems in the body(44). Nicotine, which is a tertiary amine, mediates its effects via the 
activation of different subtypes of nicotine acetylcholine receptor (nAchR)(45). The 
interaction between nicotine and various nAchR will facilitate the release of various 
neurotransmitters which include acetylcholine, dopamine, noradrenaline, serotonin, ᵞ-
aminobutyric acid (GABA) and glutamate, all of which were implicated in psychiatric 
disorders. 
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 Antipsychotic drugs block postsynaptic dopamine D2 receptors and patients with 
schizophrenia taking antipsychotic medication may smoke to restore the blocked 
dopamine effects. Thus, there may be reduction of common side effects, including 
extrapyramidal symptoms. In addition, this attenuation of side-effects may be achieved 
via the induction of enzymes, namely P450 1A2 isoform (CYP1A2) and UDP-
glucoronyltransferase caused by enzyme synthesis and is fully present 2 weeks after a 
person starts smoking and reversed 2-4 weeks after termination of smoking (46). This 
translates into decreased plasma levels of many typical and atypical antipsychotics (e.g. 
haloperidol, chlorpromazine, olanzepine and clozapine) by approximately one-third(46). 
It is therefore a finding that patients with schizophrenia who smoked heavily might be 
undertreated and might partly explain the observation that they had higher numbers of 
hospitalizations and more positive symptoms during acute relapses(47).  
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1.9 Why do patients with schizophrenia smoke? 
 Despite all the evidence that point towards the many health hazards and even high 
costs of smoking, the prevalence of schizophrenics smokers is still high. 
The explanations of why there is an elevated prevalence of smoking among 
people with severe mental illness is likely to include neurological, psychological, 
behavioural and environmental factors. 
Smoking has been found to exert multiple cognitive and behavioural effects even 
among non-psychiatric patients. Among patients with schizophrenia, smoking was 
strongly associated with subjective feelings of cheerfulness, agility, alertness, 
concentration, calmness, relaxation, habit, settling nerves, sedative effects, control of 
negative symptoms and addiction (26, 48, 49). 
Again and again, the question of why patients with schizophrenia smoke at the 
rates described by so many studies have come up. The most suggested cause for this is 
that nicotine served a form of self-medication. Patients self-medicate themselves with 
nicotine to reduce the side-effects of medication, to enhance the therapeutic effects of 
antipsychotics and so reduce negative symptoms, and/or to improve cognitive deficits 
linked to schizophrenia. In addition, cigarette smoking has also been linked to familial 
vulnerability to schizophrenia(44). 
 Studies have found that smokers on antipsychotic medication displayed less 
medication-induced parkinsonism (17, 50). In the two studies concerned, the findings 
were independent of age, gender and use of anticholinergics. Goff et al (17) also found 
the reduced frequency of neuroleptic-induced parkinsonism in the face of smoking in this 
group of patients impressive as they were also on twice as high of  doses of 
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antipsychotics. It had been established that there were excipients in the tobacco smoke 
which induced the hepatic enzyme and thus increased the metabolism of antipsychotics. 
Subsequently, the blood levels of these antipsychotics will fall. The treating psychiatrists 
will be expected to increase the dosage of their patients’ antipsychotics in response to the 
psychopathology exhibited by their patients. Therefore, to control this confounding effect 
of nicotine-induced activation of hepatic microsomal enzymes, nicotine patches have 
been used to investigate the association between medication-induced extrapyramidal 
side-effects and nicotine(51). In this particular study which involved patients treated with 
haloperidol, it was suggested that nicotine can produce clinically detectable 
improvements in bradykinesia-rigidity.  
 There have also been studies which addressed response of smoker with treatment-
resistant schizophrenia to clozapine. Studies have found that upon switching from a 
typical antipsychotic to clozapine, these patients smoked less, suggesting that the removal 
of the pharmacologic actions of dopamine of the conventional antipsychotic had some 
contribution to this effect(52). 
 Empirical clinical data have also shown that smoking can reduce negative 
symptoms without affecting the positive symptoms in patients with schizophrenia, which 
reflects nicotine’s ability to raise dopamine levels in the nucleus accumbens and 
prefrontal cortex(44). Reduction of negative symptoms for example social and emotional 
withdrawal through either psychosocial or neurochemical actions might increase patients’ 
social interaction with others, therefore reduce feelings of isolation and further reinforce 
nicotine use(48). 
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 People with schizophrenia are known to suffer from multiple sensory processing 
deficits which , include auditory sensory processing (P50 deficits), eye-tracking deficits, 
pre-pulse inhibition abnormalities (prepulse deficiencies will lead to sensory over-
stimulation and behavioural confusion) and cognitive deficiencies, all of which they 
smoke in order to self-medicate and improve these deficiencies. The loci for several 
nicotinic receptors through which nicotine acts have been genetically linked to both 
smoking and schizophrenia. One such receptor, α7* has been implicated in sensory 
gating deficits and is considered precious for cognitive functions.  However, smoking 
desensitizes this important receptor. In a groundbreaking research conducted by Leonard 
et al(53), an α7* agonist tested helped to improve P50 gating and cognition, which 
opened new grounds for research into cholinergic nicotinic drugs. In addition, nicotine 
was found to enhance visuospatial working memory and attentional deficits in patients 
with schizophrenia who smoke(54). 
 
 
 
 
 
 
 
 
 
 
19 
 
CHAPTER 2: RATIONALE OF STUDY AND OBJECTIVES 
 
2.1 Rationale of study 
There is an abundance of literature pertaining to nicotine dependence. However, 
there is a paucity of local data regarding smoking and nicotine dependence in patients 
with schizophrenia in Malaysia.  
In times when substance abuse and dependence are of major concern, nicotine 
dependence also needs due consideration. Studies in this area will help in the planning of 
programs dealing with smoking cessation. More specifically, it will help to target certain 
groups of patients identified as being at risk. Subsequently, it will help in planning health 
management programs and providing better, all-rounded care for patients with 
schizophrenia. 
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2.2 General objective 
To quantitatively assess the prevalence and associated factors of nicotine dependence and 
severity of illness in outpatients with schizophrenia in Hospital Tuanku Ja’far, Seremban 
(HTJS). 
 
2.3 Specific objectives 
1. To determine the prevalence of smoking among outpatients with schizophrenia who 
smoke in HTJS. 
2. To determine the prevalence of nicotine dependence among outpatients with 
schizophrenia who smoke in HTJS. 
3. To determine the factors associated with smoking and nicotine dependence in 
outpatients with schizophrenia in HTJS 
4. To investigate the association between smoking and nicotine dependence with the 
severity of illness in patients with schizophrenia in HTJS 
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CHAPTER 3: METHODS 
 
3.1 Study setting 
Hospital Tuanku Ja’afar, Seremban (HTJS), Negeri Sembilan is the main general 
hospital which is also the main tertiary hospital in Negeri Sembilan receiving referrals 
from other hospitals in the state. HTJS is the only hospital in Negeri Sembilan providing 
inpatient psychiatric services. HTJS psychiatric department covers the district of 
Seremban which, according to a recent census, has a population of almost 1 million. In 
addition, the HTJS psychiatric services also extend to the other districts in the state of 
Negeri Sembilan. Its services also cover areas such as Branang and Sepang in Selangor.  
The Department of Psychiatry and Mental Health, HTJ is located 1.5 km from the 
main hospital building. The department currently houses 2 main buildings, 1 meant for 
the outpatient clinic and occupational therapy unit and another for the wards.  
The outpatient clinic of the department runs from Monday to Friday, with 
Tuesdays and Thursdays allocated for follow-up cases and Mondays, Wednesdays and 
Fridays reserved for new cases. All cases are appointment-based. On clinic days, cases 
will be registered by the staff manning the registration counter. On average, a follow-up 
clinic day may record between 100-160 patients with a mixture of psychiatric diagnoses. 
50-60% of them would meet a diagnosis of schizophrenia.  
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3.2 Study design 
This is a cross-sectional study which was conducted in the outpatient psychiatric 
clinic in HTJS between August 2011 to November 2011. Follow-up cases with a 
diagnosis of schizophrenia were identified during registration by reviewing the case 
records. 
 
3.3 Sample collection 
The study population included all patients with schizophrenia who attended the 
outpatient psychiatric follow-up clinic of Hospital Tuanku Ja’afar, Seremban, during the 
study period and who met the inclusion criteria. 
 
3.3.1 Sample size calculation 
The sample size was determined by using the following formula: 
n = Z
2
  P(1-P) 
            d
2 
   = 1.96
2
 X 0.8 (1-0.8) 
                0.05
2 
   = 3.8416 X 0.8 (0.2) 
                0.0025 
= 245.8624 
In the formula shown : 
n = required sample size 
Z = confidence level at 95% ( given a standard value of 1.96) 
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P= estimated prevalence of schizophrenic patients who smoke 
d = margin of error at 5% ( given a standard value of 0.05) 
Therefore, the targeted sample size was estimated to be 250 patients with schizophrenia.  
The estimated prevalence (p) was obtained by previous studies done on outpatients with 
schizophrenia, which have found prevalences of up to 88%(13). Therefore, for this study, 
p was taken as 0.8 or 80%. 
 
3.3.2 Sampling and data collection 
This study utilized the universal sampling method. Patients attending the 
outpatient psychiatric clinic of HTJS were screened for suitability of recruitment into the 
study. Patients with a clinical diagnosis of schizophrenia were administered the Mini 
International Neuropsychiatric Interview (M.I.N.I). If they fulfilled the inclusion criteria 
and did not meet any of the exclusion criteria, they would be invited to join the study. 
They would be given an explanation regarding the study and a written informed consent 
was obtained from each subject should they agree to participate. 
Upon obtaining consent from the subjects, demographic and clinical data were 
collected. This was done via interview and information regarding previous 
hospitalizations and medication was obtained from the patient’s case notes. The Positive 
and Negative Symptom Scale (PANSS) was used to rate the severity of illness in these 
subjects. To rate the severity of nicotine dependence, the patients who smoked were 
given the Fagerstrom Test for Nicotine Dependence (FTND), either the Malay or English 
version, to complete. The interview was completed by asking the subjects to perform a 
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simple breath test that will measure the levels of carbon monoxide contained in the 
expired air. 
A total of 200 patients were approached over the study period. 19 patients were 
excluded from the study. Among the reasons for exclusion were due to language barrier, 
patients were too psychotic or disorganized and patients’ refusal to participate. Therefore, 
a total of 181 subjects were enrolled. 
 
3.3.3 Inclusion criteria 
1. Patients diagnosed with schizophrenia by using the DSM-IV criteria for 
schizophrenia. 
2. Patients aged above 18 years old who consented to participate in the study. 
3. Patients and family who are able to understand the materials presented and 
communicate any concerns or questions that they have. 
 
3.3.4 Exclusion criteria  
1. Patients who refused to participate in the study. 
2. Patients in whom the psychiatric symptoms are due to an acute medical illness. 
3. Patients who are unable to converse in Malay or English. 
4. Patients who chew tobacco. 
5. Patients who are too psychotic or who are unable to coperate. 
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3.4 Study instruments 
3.4.1 Mini International Neuropsychiatric Interview (M.I.N.I) version 6.0.0 
The Mini International Neuropsychiatric Interview (M.I.N.I.) is a short, structured 
diagnostic interview to meet the needs for a short but accurate diagnostic tool for trials 
and epidemiological studies. It was developed to assess for current and lifetime 
psychiatric disorders according to the DSM-IV ( Diagnostics and Statistical Manual for 
Mental Disorders fourth edition) and ICD-10 (International Classification of Disease 
tenth edition)criteria. It takes approximately 15-20 minutes to administer, which is less 
than the time taken with SCID (Structured Clinical Interview for DSM-IV Disorders), 
CIDI (Composite International Diagnostic Interview) or SCAN (Schedules for Clinical 
Assessment in Neuropsychiatry). 
M.I.N.I contains 16 modules and in this study, the diagnostic category K was used. 
Category K deals with delusions, hallucinations, disorganized or catatonic behavior and 
negative symptoms. It also contains questions pertaining to Mood Disorders with or 
without Psychotic Features. The M.I.N.I. has been translated into many different 
languages and has been proven to have good reliability and validity(55). 
 
3.4.2 Positive and Negative Syndrome Scale (PANSS) 
The Positive and Negative Syndrome Scale (PANSS) is a scale which was 
developed to specifically assess the positive and negative symptoms of schizophrenia and 
also general psychopathology. It contains 30 items, 7 of which are on positive symptoms, 
7 on negative symptoms and 16 on general psychopathology. PANSS is actually a 
combination of 18 items of the Brief Psychiatric Rating Scale (BPRS) and 12 items of the 
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Psychopathology Rating Schedule. All of the 30 items in PANSS are given a complete 
definition for ease of use. In addition, each rating point is also given a detailed anchoring. 
It is typically administered by clinicians who evaluate patients’ current severity level on 
each rating point by endorsing 1 of 7 weights from absent to extreme. It has demonstrated 
high internal reliability and good construct validity(56). 
 
3.4.3 Fagerstrom Test for Nicotine Dependence (FTND) 
The Fagerstrom Test for Nicotine Dependence (FTND) has been used widely to 
measure nicotine dependence. The FTND is actually an improved version of the 
Fagerstrom Tolerance Questionnaire (FTQ). The FTND was developed because FTQ had 
significant psychometric disadvantages. It has 6 items and the total scores can range 
between 0 to 10. It is a self-report questionnaire which conceptualizes nicotine 
dependence via physiological and behavioural symptoms(57). The need for 
supplementary instruments to detect the presence of nicotine dependence was supported 
by the fact that 39.4% did not meet the criteria for nicotine dependence even though the 
smoking history suggested this(58). However, this also suggests that other factors besides 
extensive nicotine use may play a part in order for nicotine dependence to occur. 
For purposes of a time-saving estimates of degree of nicotine dependence to use 
in surveys, the Heavy Smoking Index or HSI was derived from two items in the FTND, 
namely “number of cigarettes per day” (CPD) and “time to first cigarette of the day” 
(TTF) which are questions one and four in the questionnaire(59). The HSI has been found 
to be reasonably good screening tool for daily smokers with high nicotine dependence but 
for the FTND was more suited for subpopulations with low nicotine dependence(60). 
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This study utilized both the English and Malay versions (FTND_M) of FTND. 
The validity and reliability of the English version of FTND has been well established(57). 
The validation of the FTND_M was timely as the Malay language is the most often used 
language in the study population. This study followed in the wake of the validated 
FTND_M(61). At the cut-off point of  more than 2, the study by Anne Yee et al found 
that the FTND_M had the following properties: sensitivity of 70.1%, specificity of 70%, 
PPV of 79.7% and NPV of 58.3%, similar to the English version (61). The FTND_M also 
had good discriminatory ability and moderate internal consistency. 
 
3.4.4 Breath Carbon Monoxide Monitor 
A simple breath test that will measure the levels of carbon monoxide levels in the 
expired air. It is useful as a tool to obtain physiological evidence of smoking or non-
smoking. Patients were instructed to hold their breaths for 20 seconds then exhale into the 
device. Expired air was measured for an end-tidal reading of carbon monoxide. Each 
patient was given 2 trials and an average of the two readings was taken. This handheld 
device measures %COHb . Levels ranged from non-smoker to dangerously addicted 
smoker. 
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3.5 Definition of variables 
3.5.1 Smokers 
Smokers refer to study participants who were current daily smokers. These were 
obtained via self-reports obtained by the researcher from the study participants. 
 
3.5.2 Duration of illness 
Duration of illness refers to the period starting from the point where there were 
non-specific symptoms and growing functional impairment even before the more 
specific positive psychotic symptoms had emerged(62). This period has often also 
been referred to as the prodrome.    
 
3.5.3 Nicotine dependence 
Nicotine dependence was diagnosed using the Fagerstrom Test for Nicotine 
Dependence by using a cut-off point of 2.  
 
3.5.4 Chlorpromazine equivalent doses 
Dosage of each medication and depot medication was converted to 
chlorpromazine equivalent dosages according to conversion tables published by 
previous studies(63-65). 
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3.6  Ethical considerations 
This study was registered with the National Medical Research Registry of the 
Ministry of Health, Malaysia. The Ministry of Health Medical Research Ethical 
Committee provided the ethical approval for this study. Upon entrance into the study, the 
selected subjects were also required to sign a written informed consent. 
 
3.7 Statistical analyses 
Analyses of data was performed using the Statistical Package for Social Studies 
(SPSS) version 19.0 to generate the relevant descriptive epidemiological statistics. 
 The baseline characteristics of the study subjects were analysed using descriptive 
statistics. Univariate analyses using chi-square test and Fisher’s exact test (if frequency in 
a cell was less or equals to 5) were performed to compare the smokers and non-smokers 
across all the demographic and clinical characteristics which were dichotomised 
accordingly. The same analysis was performed again but now with regards to nicotine 
dependence.  
Comparison of the means of PANSS score and all its subscales and Fagerstrom 
scores were done using the t-test. This was done to analyse the association between 
disease severity and nicotine dependence with the sociodemographic and clinical 
characteristics of the study subjects. For all the variables found to be significant via 
univariate analyses, multivariate analyses was then performed using logistic regression to 
control for all possible confounders.  
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Spearman’s correlation was used to analyse the association between PANSS score, 
its subscales and Fagerstrom scores. 
P values of less than 0.05 were taken as statistically significant for the relevant 
tests that were performed. 
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CHAPTER 4: RESULTS 
4.1 SOCIODEMOGRAPHIC CHARACTERISTICS 
Table 1: Sociodemographic characteristics of the study participants. 
Characteristics  n % Mean SD 
Age    41.42 11.42 
Gender Male  116 64.10   
 Female 65 35.90   
Ethnicity Malay  83 45.10   
 Chinese 70 38.70   
 Indian 28 15.50   
Marital status Single 122 67.40   
 Married 56 30.90   
 Divorced 3 1.70   
Current occupation  
Professional/technical/ 
managerial 
Military / police / fireman 
Factory worker 
Clerical / sales 
Service 
Homemaker / housewife 
Own business 
Student  
Others 
Unemployed 
Retired 
 
2 
7 
2 
3 
20 
20 
5 
1 
38 
82 
1 
 
1.10 
3.90 
1.10 
1.70 
11.00 
11.00 
2.80 
0.60 
21.00 
45.90 
0.60 
  
Total income ≤RM500 135 74.60   
 RM501-1000 30 16.60   
 RM1001-2000 8 4.40   
 RM2001-3000 7 3.90   
 >RM3000 1 0.60   
Education level Primary 25 13.80   
 Secondary 128 70.70   
 College / university 27 14.90   
 Nil 1 0.60   
SD = standard deviation 
32 
 
 Out of the 200 patients approached for this study, 181 patients fulfilled the 
inclusion criteria and were recruited and agreed to participate. Table 1 demonstrates the 
sociodemographic characteristics of the study participants. 
The mean age of the study participants was 41.42 years old, with a standard 
deviation of 11.42(Table 1). Most of them were at least 40 years old (53.6%) and the 
remaining 46.4% were less than 40 years of age. 
Males made up 64.1% (n=116) of the study participants, and the remaining 35.9% 
were females. Most of the study participants (45%) were Malays, followed by 38.7% 
Chinese and 15.5% Indians. The majority of the study participants were single (67.4%), 
while 56 (30.9%) of them were divorced at the time of recruitment.  
A large number of the study participants were not working at the time of 
interview (n=82, 45.9%). Housewives and those in the fields of service (waiter / maid / 
security guard) each made up another 20% of the study participants. Most of the study 
participants were in the low socioeconomic group, whereby 74.6% of them had a 
personal income of less than RM500 per month. The rest of the study participants earned 
more than RM500 per month. Only one participant had a personal income of more than 
RM3000 per month. 
One hundred twenty-eight participants or 70.7% had studied until secondary 
school. Another 27 of them or 14.9% had went to college or university, 13.8% obtained 
only primary education and 1 participant did not receive any formal education.  
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Figure 1: Age distribution of the study participants 
 
 
 
 
 
 
 
 
 
Mean =  41.42 
SD = 11.42 
N = 180  
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4.2 CLINICAL CHARACTERISTICS 
Table 2: Clinical characteristics of study participants 
 N % Mean SD 
Duration of illness (years)   14.99 10.07 
Duration of smoking (years)   19.94 11.30 
Age start smoking (years)   19.68 6.25 
Number of cigarettes smoked   16.55 9.30 
Breath CO levels 
Smokers 
 
Non-smokers 
   
ppm        13.91         
COHb     3.16 
ppm        2.22 
COHb     1.02     
 
3.16 
2.15 
0.65 
0.09 
Number of hospitalisations   1.73 2.63 
Chlorpromazine equivalent (mg)   285.66 400.12 
Total PANSS score 
PANSS positive subscale score 
PANSS negative subscale score 
PANSS general psychopathology 
subscale score 
  50.04 
8.98 
17.39 
23.22 
2.36 
2.97 
5.84 
5.18 
Total FTND score   4.16 10.73 
Oral typical antipsychotics No 
Yes 
108 
73 
59.70 
40.30 
Oral atypical antipsychotics No 
Yes 
82 
99 
45.30 
54.70 
Anticholinergic No 
Yes 
48 
133 
26.50 
73.50 
Depot antipsychotics No 
Yes 
111 
70 
61.30 
38.70 
Benzodiazepines No 
Yes 
160 
21 
88.40 
11.60 
Antidepressants No 
Yes 
172 
9 
95.00 
5.00 
Family history of smoking No 
Yes 
67 
114 
37.00 
63.00 
SD = standard deviation 
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 Clinical characteristics of the study participants are as shown in Table 2. 
 The mean duration of schizophrenia in the participants was 14.99 years with a 
standard deviation of 10.07.  
Those participants who smoked had been smoking for a mean of 19.94 years and 
they had started smoking at a range of between 10 to 43 years old, with a mean of 19.68 
years (SD 6.25). The mean number of cigarettes smoked was 16.55 (SD 9.30) with a 
range of 2 to 40 sticks a day.  
 Measurements of carbon monoxide levels in the expired air using a handheld 
device showed that the non-smokers had levels within the acceptable range. The mean for 
smokers of 13.91 ppm indicated that they were addicted to nicotine.  
The mean number of hospitalisations was 1.73 (SD 2.63), whereby 38.1% of the 
study participants had never been hospitalised. 
 With regards to medication use, dosage of all medications were converted to 
Chlorpromazine equivalent doses(63, 66). However, it was found to be not normally 
distributed, with a median of 200 mg/day. There were more patients on oral atypical 
(54.7%, n=99) antipsychotics as opposed to oral typical antipsychotics (40.3%, n=73). 
There were only 4 patients who were on both oral typical and atypical antipsychotics. 
Therefore, analysis was not performed for this variable. Seventy participants (n=38.7%) 
were on depot antipsychotics, all of which were the typical depot injections, namely 
fluphenazine decanoate, flupenthixol decanoate and zuclopenthixol decanoate. 
Anticholinergics were taken by 133 participants (73.5%) , 11.6% (n=21) on 
benzodiazepines and 9(5%) were on antidepressants.  
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 The mean total PANSS score was 50.04 (SD = 2.36) and mean total FTND score 
was 4.16 (SD = 10.73).  
The study also found that 37% (n=67) of the study participants had a positive 
family history of smoking. 
Figures 2 and 3 below shows the distribution of the total PANSS and FTND 
scores of the study participants, both of which were found to be normally distributed. 
  
Figure 2: Distribution of total PANSS scores among the study participants 
 
 
Mean = 50.04 
SD = 10.73 
N = 181 
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Figure 3: Distribution of total FTND scores among the study participants 
 
 
 
 
 
 
 
 
 
 
Mean = 4.16 
SD = 2.36 
N = 69 
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4.3 PREVALENCE OF SMOKING AND NICOTINE DEPENDENCE 
Table 3: Prevalence of smoking and nicotine dependence in the study participants 
  N % 
Smoking status Smoker 69 38.1 
 Non-smoker 96 53.0 
 Ex-smoker 16 8.8 
Nicotine dependence Yes 
No 
51 
18 
73.9 
26.1 
 
 The prevalence of smoking in the study participants was performed by asking the 
patients directly regarding their smoking habits. This was further confirmed by asking 
accompanying relatives or persons.  
The prevalence of smoking in this group of patients with schizophrenia was found 
to be 38.1% (n=69). Non-smokers and ex-smokers accounted for the remainder 61.8% (n 
= 112). A sub-analysis of the participants who were currently not smoking found that 
8.8% of them were actually ex-smokers. 
 Nicotine dependence, diagnosed using the Fagerstrom Test for Nicotine 
Dependence (FTND, Malay or English version) found a total of 51 or 73.9% to be 
dependent on nicotine. The remainder 18 study participants or 26.1% had total FTND 
scores of more than two and were therefore considered not dependent on nicotine. 
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 Figure 4: Prevalence of smoking among the study participants 
                                         
              
Non-smoker
62%
Smoker
38%
 
Figure 5: Prevalence of nicotine dependence among the study participants                                                     
Not dependent
26%
Dependent
74%
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4.4 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS, CLINICAL 
CHARACTERISTICS AND PANSS SCORES WITH SMOKING STATUS 
Table 4: Univariate analysis of association between sociodemographic and clinical 
characteristics with smoking status using chi square test 
 Smoking status Chi 
square 
p value OR 95% CI 
Yes 
n(%) 
No 
n (%) 
Age    
<40 years old 
≥40 years old 
 
42 (50.0) 
27(27.8) 
 
42(50.0) 
70(72.2) 
 
9.38 
 
p<0.01* 
 
2.60 
 
1.4 - 4.803 
Gender 
Male 
Female 
 
68(58.6) 
1(1.5) 
 
48(41.4) 
64(98.5) 
 
57.54 
 
p<0.01*
#
 
 
 
90.68 
 
12.155 – 676.321 
Ethnicity 
Malay 
Non-Malay 
 
41(49.4) 
28(28.6) 
 
42(50.6) 
70(71.4) 
 
8.26 
 
p<0.01* 
 
2.44 
 
1.32-4.51 
Marital status 
Married 
Not married 
 
17(30.4) 
52(41.6) 
 
39(69.6) 
73(58.4) 
 
2.07 
 
0.15 
 
0.61 
 
0.313 – 1.198 
 
Employment status 
Employed 
Unemployed 
 
41(42.7) 
28(32.9) 
 
55(57.3) 
57(67.1) 
 
1.82 
 
0.18 
 
1.52 
 
0.83-2.78 
Total income 
≤RM500 
>RM500 
 
43(31.9) 
26(56.5) 
 
92(68.1) 
20(43.5) 
 
8.85 
 
0.03* 
 
0.36 
 
0.18-0.71 
Education level 
Primary and below 
Secondary / tertiary 
 
10(38.5) 
59(38.1) 
 
16(61.5) 
96(61.9) 
 
0.01 
 
0.97 
 
1.02 
 
0.433-2.39 
Drug and alcohol  
Yes 
No 
 
19(90.5) 
50(31.3) 
 
2(9.5) 
110(68.8) 
 
27.60 
 
p<0.01*
#
 
 
20.90 
 
4.69 – 93.19 
Duration of illness
+
 
12 years or less 
More than 12 years 
 
45(43.3) 
24(31.2) 
 
59(56.7) 
53(68.8) 
 
2.75 
 
0.09 
 
1.68 
 
0.91-3.13 
Number of 
hospitalisations 
2 or less 
More than 2 
 
 
21(30.0) 
48(43.2) 
 
 
49(70.0) 
63(56.8) 
 
 
3.19 
 
 
0.07 
 
 
0.56 
 
 
0.30-1.06 
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Chlorpromazine 
equivalent (mg)
+
 
≤200mg/day 
>200 mg/day 
 
 
31(32.6) 
38(44.2) 
 
 
64(67.4) 
48(55.8) 
 
 
2.56 
 
 
0.11 
 
 
0.61 
 
 
0.33-1.12 
Typical antipsychotics 
Yes 
No 
 
19(27.1) 
50(45.0) 
 
51(72.9) 
61(55.0) 
 
5.83 
 
0.02* 
 
0.46 
 
0.24-0.87 
Atypical antipsychotics 
Yes 
No 
 
45(46.0) 
24(29.0) 
 
53(54.0) 
59(71.0) 
 
5.51 
 
0.02* 
 
2.09 
 
1.12-3.88 
Anticholinergic 
Yes 
No 
 
54(40.6) 
15(31.3) 
 
79(59.4) 
33(68.7) 
 
1.31 
 
0.25 
 
1.5 
 
0.75-3.00 
Depot antipsychotics 
Yes 
No 
 
32(46.4) 
37(33.0) 
 
37(53.6) 
75(67.0) 
 
3.22 
 
 
0.07 
 
1.75 
 
0.95-3.20 
Benzodiazepines 
Yes 
No 
 
11(52.4) 
58(36.3) 
 
10(47.6) 
102(63.7) 
 
2.05 
 
0.16 
 
1.93 
 
0.78-4.83 
Antidepressants 
Yes 
No 
 
1(11.1) 
68(39.5) 
 
8(88.9) 
104(60.5) 
 
2.93 
 
0.87
#
 
 
0.19 
 
0.02-1.56 
Family history of 
smoking 
Yes 
No 
 
 
54(47.4) 
15(22.4) 
 
 
60(52.6) 
52(77.6) 
 
 
11.16 
 
 
p< 0.01* 
 
 
3.12 
 
 
1.58 – 6.17 
*p < 0.05, # Fisher’s exact test 
OR = odds ratio, CI=confidence interval 
 
 In order to perform univariate analysis, variables such as age, ethnicity, marital 
status, employment status, total income, education level, duration of illness, number of 
hospitalisations and chlorpromazine equivalent dosage were dichotomized. 
Dichotomizing these variable would allow the calculation of odds ratio in the univariate 
analyses(21). All of the afore-mentioned variables were normally distributed except for 
duration of illness and chlorpromazine equivalent dosage. 
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 Analysis of the sociodemographic variables showed several significant findings. 
Smokers were more likely to be in the younger age group (less than 40 years old, OR = 
2.6). Smokers were also more likely to be male, Malays, with a total monthly income of 
more than RM500. Being unmarried appeared to be associated with smoking but it was 
not statistically significant.   
Analysis of the clinical variables showed that those taking drugs or alcohol was 
associated with a higher prevalence of smoking. It also appeared that smokers were more 
likely to have been hospitalised more than twice during the duration of illness. However, 
it was not statistically significant.  
Smokers were also found to be twice as likely to be taking atypical antipsychotics 
and had a 3.12 odds ratio of a family history of smoking. It also showed with statistical 
significance that smokers were less likely to be taking oral typical antipsychotics. They 
were also more likely to be associated with smoking more than 20 cigarettes per day.  
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Table 5: Univariate analysis of association between total PANSS score and subscale 
scores with smoking status using chi square 
 Smoking status Chi 
square 
p value OR 95% CI 
 
 
 
 
Yes  
n(%) 
No  
n(%) 
 
 
 
 
 
 
 
 
 
PANSS total score 
<50 
 
 
33(34.0) 
 
 
64(66.0) 
 
 
1.49 
 
 
0.22 
 
 
0.69 
 
 
0.28-1.26 
≥50 36(42.9) 48(57.1)     
PANSS positive subscale 
score 
      
<9 27(26.0) 77(74.0) 15.32 p<0.05* 0.29 0.16-0.55 
≥9 42(54.5) 35(45.5)     
PANSS negative subscale 
score 
      
<17 36(41.9) 50(58.1) 0.97 0.32 1.35 0.74-2.47 
≥17 33(34.7) 62(65.3)     
PANSS general 
psychopathology subscale 
score 
      
<23 25(27.2) 67(72.8) 9.51 p<0.05* 0.38 0.21-0.71 
≥23 44(49.4) 45(50.6)     
*p <0.05, # Fisher’s exact test 
OR = Odds Ratio, CI = Confidence Interval 
 
 To perform this analysis, the total PANSS score and all 3 of the subscale scores 
were dichotomised, as shown in the table above. All of these scores were found to be 
normally distributed when tested using the Kolmogorov-Smirnov test. 
 Two PANSS subscales were found to be significantly associated with smoking 
status. Participants who smoked were more likely to have scored at least 9 in the positive 
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subscale score. Those who smoked were also more likely to score 23 or higher on the 
general psychopathology subscale score. 
 Although it appeared that the smoking participants scored higher in total on the 
PANSS and lower on the negative subscale, these were not statistically significant when 
the chi square test was performed.  
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Table 6: Multivariate analysis between sociodemographic, clinical characteristics and 
PANSS scores with smoking status among the study participants using logistics 
regression 
 B S.E. P Adjusted OR 95% C.I. 
 Age 
<40 years old 
≥40 years old 
 
0.89 
 
 
0.46 
 
0.05 
 
2.43 
 
0.99 – 5.93 
Gender 
Male 
Female 
 
4.13 
 
1.06 
 
p<0.01* 
 
62.36 
 
7.89 – 492.89 
Ethnicity 
Malay 
Non-Malay 
 
1.11 
 
0.46 
 
0.02* 
 
3.03 
 
1.22 – 7.50 
Total income 
≤RM500 
>RM500 
 
-0.84 
 
0.86 
 
p<0.01* 
 
0.43 
 
0.16 – 1.17 
Drug and alcohol 
Yes 
No 
 
2.56 
 
0.86 
 
p<0.01* 
 
12.96 
 
2.41 – 69.60 
Typical antipsychotics 
Yes 
No 
 
-0.81 
 
0.80 
 
0.31 
 
0.45 
 
0.09 – 2.13 
Atypical antipsychotics 
Yes 
No 
 
-0.40 
 
0.78 
 
0.61 
 
0.67 
 
0.15 – 3.08 
Family history 
Yes 
No 
 
0.17 
 
0.50 
 
0.73 
 
1.18 
 
0.45 – 3.14 
 Total positive 
<9 
≥9 
 
-0.49 
 
0.48 
 
0.30 
 
0.61 
 
0.24 – 1.56 
 Total psychopathology 
<23 
≥23 
 
-0.11 
 
3.46 
 
0.83 
 
0.90 
 
0.34 – 2.34 
*p<0.05 
SE = standard error, OR = odds ratio, CI = confidence interval 
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Multivariate analysis between sociodemographic, clinical characteristics and 
PANSS scores with smoking status revealed statistically significant association between 
gender, ethnicity, total income earned and use of drugs and alcohol, 
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4.5 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS, CLINICAL 
CHARACTERISTICS AND PANSS SCORES WITH NICOTINE DEPENDENCE 
Table 7: Univariate analysis between sociodemographic factors and clinical 
characteristics with nicotine dependence among smokers using chi square 
 Nicotine dependence Chi square p value OR 95% CI 
Yes 
n(%) 
No 
n (%) 
Age    
<40 years old 
≥40 years old 
 
30(71.4) 
21(77.8) 
 
12(28.6) 
6(22.2) 
 
0.34 
 
 
0.558 
 
0.71 
 
0.23-2.21 
Gender 
Male 
Female 
 
51(75.0) 
0(0) 
 
17(25.0) 
1(100.0) 
 
2.88 
 
0.26
#
 
 
 
0.25 
 
0.17-0.38 
Ethnicity 
Malay 
Non-Malay 
 
31(75.6) 
20(71.4) 
 
10(24.4) 
8(28.6) 
 
0.15 
 
0.7 
 
1.24 
 
0.42-3.68 
Marital status 
Married 
Not married 
 
14(82.4) 
37(71.2) 
 
3(17.6) 
15(28.8) 
 
0.83 
 
 
0.53
#
 
 
1.9 
 
0.47-7.55 
 
Employment status 
Employed 
Unemployed 
 
31(75.6) 
20(71.4) 
 
10(24.4) 
8(28.6) 
 
0.15 
 
0.7 
 
1.24 
 
0.42-3.68 
Total income 
≤RM500 
>RM500 
 
30(69.8) 
21(80.8) 
 
13(30.2) 
5(19.2) 
 
1.02 
 
0.31 
 
0.55 
 
0.17-1.78 
Education level 
Primary and below 
Secondary / tertiary 
 
7(70.0) 
44(74.6) 
 
3(30.0) 
15(25.4) 
 
0.93 
 
 
0.76 
 
0.8 
 
0.18-3.47 
Drug and alcohol  
Yes 
No 
 
16(84.2) 
35(72.9) 
 
3(15.8) 
15(27.1) 
 
1.44 
 
0.23 
 
2.29 
 
0.58-9.03 
Duration of illness 
≤15 years 
>15 years 
 
32(71.1) 
19(79.2) 
 
13(28.9) 
5(20.8) 
 
0.53 
 
0.468 
 
0.65 
 
0.2-2.1 
Number of hospitalisations 
≤2 
>2 
 
14(66.7) 
37(77.1) 
 
7(33.3) 
11(22.9) 
 
0.82 
 
0.37 
 
0.6 
 
0.19-1.84 
Chlorpromazine equivalent (mg) 
≤200 mg/day 
>200 mg/day 
 
31(32.6) 
38(44.2) 
 
64(67.4) 
48(55.8) 
 
2.56 
 
0.11 
 
0.61 
 
0.33-1.12 
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Typical antipsychotics 
Yes 
No 
 
15(78.9) 
36(72.0) 
 
4(21.1) 
14(28.0) 
 
0.35 
 
0.761
#
 
 
 
1.46 
 
 
0.41-5.16 
Atypical antipsychotics 
Yes 
No 
 
33(73.3) 
18(75.0) 
 
12(26.7) 
6(25.0) 
 
0.23 
 
0.88 
 
 
0.92 
 
 
0.29-2.86 
 
Anticholinergic 
Yes 
No 
 
39(72.2) 
12(80.0) 
 
15(27.8) 
3(20.0) 
 
0.37 
 
0.74
#
 
 
0.65 
 
0.16-2.63 
Depot antipsychotics 
Yes 
No 
 
25(78.1) 
26(96.3) 
 
7(21.9) 
11(3.7) 
 
0.55 
 
0.46 
 
1.51 
 
0.51-4.52 
Benzodiazepines 
Yes 
No 
 
7(40.5) 
44(75.9) 
 
4(59.5) 
14(24.1) 
 
0.72 
 
0.46
#
 
 
0.56 
 
0.14-2.19 
Antidepressants 
Yes 
No 
 
1(100.0) 
50(73.5) 
 
0(0) 
18(26.5) 
 
0.36 
 
0.11
#
 
 
1.36 
 
1.18-1.57 
Duration of smoking 
<19 years 
≥19 years 
 
23(67.6) 
28(80.0) 
 
11(32.4) 
7(20.0) 
 
1.37 
 
0.24 
 
0.52 
 
0.18 - 1.57 
Age start smoking 
<20 years old 
≥20 years old 
 
31(72.1) 
20(76.9) 
 
12(27.9) 
6(23.1) 
 
0.20 
 
0.66 
 
0.78 
 
0.25 - 2.40 
Family history of smoking 
Yes 
No 
 
37(68.5) 
14(93.3) 
 
17(31.5) 
1(6.7) 
 
3.75 
 
0.09
#
 
 
0.16 
 
0.19-1.28 
*p <0.05, # Fisher’s exact test 
OR = Odds Ratio, CI = Confidence Interval 
 
 Results of the analysis to find an association between participants’ 
sociodemographic and clinical characteristics with nicotine dependence are shown in 
Table 7. However, no variables were found to statistically significant with nicotine 
dependence.  
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Table 8: Univariate analysis of association between total PANSS score and subscale 
scores with nicotine dependence using chi square 
 Nicotine dependence 
 
Chi 
square 
OR Adjusted 
OR 
95% CI for 
Adjusted OR 
p 
value 
Yes 
n(%) 
No 
n(%) 
PANSS total score 
<50 
 
≥50 
 
33(34.0) 
 
36(42.9) 
 
64(66.0) 
 
48(57.1) 
 
1.49 
 
0.68 
 
0.79
a
 
 
0.24 – 2.57 
 
0.69 
PANSS positive subscale 
score 
<9 
≥9 
 
 
27(26.0) 
42(54.5) 
 
 
77(74.0) 
35(45.6) 
 
 
15.32 
 
 
0.29 
 
 
0.47
a
 
 
 
0.15 – 1.50 
 
 
0.20 
PANSS negative subscale 
score 
<17 
≥17 
 
 
36(41.9) 
33(34.7) 
 
 
50(58.1) 
62(65.3) 
 
 
0.97 
 
 
1.35 
 
 
1.12
a 
 
 
0.35 – 3.62 
 
 
0.85 
PANSS general 
psychopathology subscale 
score 
<23 
≥23 
 
 
 
25(27.2) 
44(49.4) 
 
 
 
67(72.8) 
45(50.6) 
 
 
 
9.51 
 
 
 
0.38 
 
 
 
1.04
a 
 
 
 
0.32 – 3.38 
 
 
 
0.95 
# Fisher’s exact test, * p<0.05 
a
 Adjusted for gender, ethnicity, total income and drug and alcohol 
OR = Odds Ratio, CI = Confidence Interval 
 
 Table 8 depicts the results of the univariate analysis which was performed to find 
the association between total PANSS score and the 3 subscale scores with nicotine 
dependence.  
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 Statistically significant association was found between the PANSS positive 
subscale score and PANSS general psychopathology subscale score with nicotine 
dependence. Scores of 9 or more on the positive subscale and 23 or more on the general 
psychopathology subscale were associated with nicotine dependence. 
 Even though no significant association was found between any of the 
sociodemographic and clinical characteristics of the study participants with nicotine 
dependence, multivariate analysis was performed with the variables found significant 
with regards to smoking status (refer to Table 6).Each of the PANSS total score, PANSS 
positive, negative and general psychopathology subscale scores were adjusted for gender, 
ethnicity, total income and drug and alcohol use. However, no statistically significant 
findings were obtained. 
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4.6 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS, CLINICAL 
CHARACTERISTICS AND PANSS SCORES WITH TOTAL FTND SCORES 
Table 9: Analysis of association between sociodemographic and clinical characteristics 
with total FTND scores using t-test 
 Mean (SD) Mean 
difference 
t P 95%CI 
Age    
<40 years old 
>40 years old 
 
3.86(2.15) 
4.63(2.66) 
 
-0.77 
 
-1.33 
 
0.19 
 
-1.93-0.38 
Gender 
Male 
Female 
 
4.21(2.35) 
1.00 
 
3.21 
 
1.36 
 
0.18 
 
-1.51-7.93 
Ethnicity 
Malay 
Non-Malay 
 
4.34(2.19) 
3.89(2.62) 
 
0.45 
 
0.77 
 
0.44 
 
-0.71-1.61 
Marital status 
Married 
Not married 
 
4.35(2.06) 
4.10(2.47) 
 
0.26 
 
0.39 
 
0.70 
 
-1.07-1.58 
Employment status 
Employed 
Unemployed 
 
4.24(2.38) 
4.04(2.38) 
 
0.21 
 
0.36 
 
0.72 
 
-0.96-1.37 
Total income 
≤RM500 
>RM500 
 
3.93(2.34) 
4.54(2.39) 
 
-0.61 
 
-1.04 
 
0.30 
 
-1.78-0.56 
Education level 
Primary and below 
Secondary / tertiary 
 
4.00(2.71) 
4.19(2.32) 
 
-0.19 
 
-0.23 
 
0.82 
 
-1.81-1.44 
Drug and alcohol  
Yes 
No 
 
4.74(2.38) 
3.94(2.34) 
 
0.80 
 
1.26 
 
0.21 
 
-0.47-2.06 
Duration of illness 
12 years or less 
More than 12 years 
 
3.58(2.07) 
4.97(2.53) 
 
-1.39 
 
-2.51 
 
0.02* 
 
-2.50- -0.28 
Number of 
hospitalisations 
2 or less 
More than 2 
 
 
3.57(1.99) 
4.42(2.48) 
 
 
-0.85 
 
 
-1.38 
 
 
0.17 
 
 
-0.27-0.38 
Chlorpromazine 
equivalent (mg) 
≤200 mg/day 
>200 mg/day 
 
 
3.61(2.19) 
4.61(2.43) 
 
 
-0.99 
 
 
-1.76 
 
 
0.08 
 
 
-2.12-0.13 
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Typical antipsychotics 
Yes 
No 
 
4.53(2.61) 
4.02(2.27) 
 
0.51 
 
0.79 
 
0.43 
 
-0.77-1.78 
Atypical 
antipsychotics 
Yes 
No 
 
4.13(2.32) 
4.21(2.48) 
 
-0.08 
 
-0.125 
 
0.90 
 
-1.275-1.12 
Anticholinergic 
Yes 
No 
 
4.11(2.38) 
4.33(2.35) 
 
-0.22 
 
-0.32 
 
0.75 
 
-1.61-1.16 
Depot antipsychotics 
Yes 
No 
 
4.31(2.44) 
4.03(2.32) 
 
0.29 
 
0.50 
 
0.62 
 
-0.86-1.43 
Benzodiazepines 
Yes 
No 
 
3.82(2.68) 
4.22(2.32) 
 
-0.41 
 
-0.52 
 
0.61 
 
-1.97-1.15 
Antidepressants 
Yes 
No 
 
6.00 
4.13(2.34) 
 
1.87 
 
0.78 
 
0.44 
 
-2.89-6.63 
Family history of 
smoking 
Yes 
No 
 
 
3.93(2.40) 
5.00(2.07) 
 
 
-1.07 
 
 
-1.58 
 
 
0.12 
 
- 
2.44-0.29 
* p <0.05 
SD= standard deviation, CI = Confidence Interval 
 
 After running the t-test for association between sociodemographic and clinical 
characteristics with total FTND scores, only one variable was found to be statistically 
significant. Study participants who had been ill for more than 12 years was found to be 
associated with higher total FTND scores (mean 4.97 SD 2.53). 
 Participants who had been hospitalised more than twice in the past, were on more 
than 200 mg/day of chlorpromazine equivalent dose of medication and those without a 
family history of smoking seemed to have higher FTND scores but these were not 
statistically significant. 
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Table 10: Analysis of association between total PANSS score and subscale scores with 
total FTND score 
 Mean 
(SD) 
Mean 
difference 
T p 95% CI 
Total PANSS score 
<50 
≥50 
 
4.03(2.35) 
4.28(2.40) 
 
-0.247 
 
-0.43 
 
0.67 
 
-1.39-0.90 
Total positive subscale score 
<9 
≥9 
 
3.74(2.58) 
4.43(2.20) 
 
-0.69 
 
-1.18 
 
0.24 
 
-1.85-0.47 
Total negative subscale score 
<17 
≥17 
 
4.25(2.26) 
4.06(2.50) 
 
0.19 
 
0.33 
 
-0.47 
 
-0.95-1.33 
Total general psychopathology subscale 
score 
<23 
≥23 
 
 
4.12(2.28) 
4.18(2.43) 
 
 
-0.062 
 
 
-0.14 
 
 
0.92 
 
 
-1.25-1.13 
SD= standard deviation, CI= confidence interval 
 Analysis of association between PANSS scores and smoking status revealed that 
smoking was associated with higher scores on the positive subscale and general 
psychopathology subscale scores. However, this association was not seen when the same 
analysis was performed with nicotine dependence. There was also no association with the 
other two subscales. 
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4.7 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND 
CLINICAL CHARACTERISTICS WITH PANSS TOTAL SCORES 
Table 11: Association between sociodemographic and clinical characteristics with total 
PANSS score using t-test 
 PANSS 
Mean(SD) 
Mean 
diff 
t P 95% CI 
Age    
<40 years old 
>40 years old 
 
51.74(11.37) 
48.57(9.96) 
 
3.17 
 
2.00 
 
0.05 
 
0.42-6.30 
Gender 
Male 
Female 
 
51.42(11.60) 
47.57(8.50) 
 
3.85 
 
2.35 
 
0.02* 
 
 
0.61-7.09 
Ethnicity 
Malay 
Non-Malay 
 
49.73(11.74) 
50.30(9.84) 
 
-0.56 
 
-0.35 
 
0.73 
 
-3.73 – 2.60 
Marital status 
Married 
Not married 
 
46.11(9.59) 
51.80(10.78) 
 
-5.69 
 
-3.40 
 
p<0.01* 
 
-9.00- -2.39 
Employment status 
Employed 
Unemployed 
 
47.83(9.182) 
52.53(11.81) 
 
-4.70 
 
-3.01 
 
p<0.01* 
 
 
-7.780- -1.162 
Total income 
<RM500 
>RM500 
 
50.96(10.93) 
47.33(9.73) 
 
3.64 
 
2.00 
 
0.04* 
 
0.05-7.22 
Education level 
Primary and below 
Secondary / tertiary 
 
48.77(8.83) 
50.25(11.023) 
 
-1.48 
 
-6.51 
 
0.52 
 
-5.98-3.01 
Drug and alcohol  
Yes 
No 
 
53.86(9.86) 
49.54(10.76) 
 
4.32 
 
1.75 
 
0.08 
 
-5.65-9.20 
Duration of illness 
15 years or less 
More than 15 years 
 
50.01(11.01) 
50.07(10.49) 
 
-0.06 
 
-0.04 
 
0.97 
 
-3.21-3.10 
 
Number of hospitalisations 
2 or less 
More than 2 
 
46.97(10.42) 
51.00(10.51) 
 
-5.00 
 
-3.13 
 
p<0.01* 
 
-8.16- -1.85 
Chlorpromazine equivalent (mg) 
≤200 mg/day 
>200 mg/day 
 
48.83(10.42) 
51.37(10.96) 
 
-2.54 
 
-1.60 
 
0.11 
 
-5.68 – 0.60 
Typical antipsychotics 
Yes 
No 
 
47.54(9.37) 
51.61(11.26) 
 
-4.07 
 
-2.52 
 
 
0.01* 
 
-7.25- -0.89 
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Atypical antipsychotics 
Yes 
No 
 
51.97(11.69) 
47.76(9.01) 
 
4.21 
 
2.68 
 
0.01* 
 
1.11-7.32 
Anticholinergic 
Yes 
No 
 
50.76(10.14) 
48.04(12.11) 
 
2.72 
 
1.51 
 
 
0.13 
 
-0.834- 6.27 
Depot antipsychotics 
Yes 
No 
 
50.26(10.81) 
49.90(10.73) 
 
0.36 
 
0.22 
 
0.83 
 
-2.90-3.61 
Benzodiazepines 
Yes 
No 
 
51.24(8.13) 
49.88(11.03) 
 
1.36 
 
0.54 
 
0.59 
 
-3.57-6.28 
Antidepressants 
Yes 
No 
 
52(13.90) 
49.94(10.58) 
 
2.06 
 
0.56 
 
 
0.58 
 
-5.19-9.32 
Family history of smoking 
Yes 
No 
 
50.82(10.44) 
48.72(11.15) 
 
2.10 
 
1.27 
 
0.20 
 
-1.15-5.35 
Smoking status 
Smoker 
Non-smoker 
 
51.52(11.32) 
49.13(10.29) 
 
2.40 
 
1.47 
 
0.20 
 
-1.15-5.35 
Nicotine dependence 
Yes 
No 
 
52.27(12.43) 
49.16(9.9) 
 
3.11 
 
1.77 
 
0.08 
 
-0.36 – 6.60 
# - Fisher’s exact test, * - p<0.05, SD = standard deviation, CI = Confidence Interval 
 Table 8 depicts the association between sociodemographic and clinical 
characteristic with the mean of total PANSS scores.  
 Male participants were associated with higher total PANSS score and it was 
statistically significant. Being married, unemployed and with a total personal monthly 
income of RM500 or less was also associated with higher total PANSS scores, all of 
which are also statistically significant.  
 Clinical characteristics with regards to number of hospitalisations, usage of oral 
antipsychotics were also found to be statistically significant. Participants who has had 
more than 2 admissions to the psychiatric ward, not on typical oral antipsychotics and 
taking oral atypical antipsychotics were associated with higher PANSS scores.    
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Table 12: Multivariate analysis of Total PANSS score among the study participants using 
multiple linear regression 
 Adjusted 
difference 
p 95% CI 
Gender -2.75 0.09  -5.92 – 0.42 
Marital status 4.31 0.01* 1.09 – 7.52 
Employment status 3.34 0.07 -0.25 – 6.92 
Total income -1.46 0.49 -5.60 – 2.69 
Number of hospitalisations 3.47 0.03* 0.42 – 6.53 
Oral typical antipsychotics 0.14 0.96 -5.09 – 5.37 
Oral atypical antipsychotics -3.56 0.17 -8.66 – 1.53 
*p<0.05 
 
Variables that were found to be statistically significant in univariate analysis were 
then included into the multivariate analysis of the total PANSS score. As shown in the 
table above, marital status and the number of hospitalisations were significantly 
associated with total PANSS scores after adjusting for other possible confounders, 
namely gender, employment status, total monthly income and the use of either typical or 
atypical antipsychotics. 
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4.8 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND 
CLINICAL CHARACTERISTICS WITH POSITIVE SYMPTOM SUBSCALE 
SCORE 
Table 13: Association between sociodemographic and clinical characteristics with 
positive subscale score using t-test 
 Mean (SD) Mean 
difference 
t P 95% CI 
Age    
<40 years old 
≥40 years old 
 
9.31(2.91) 
8.69(3.01) 
 
0.62 
 
1.40 
 
0.16 
 
-0.25-1.49 
Gender 
Male 
Female 
 
9.40(3.31) 
8.23(2.08) 
 
1.17 
 
2.57 
 
0.01* 
 
0.27-2.06 
Ethnicity 
Malay 
Non-Malay 
 
9.33(3.17) 
8.68(2.78) 
 
0.64 
 
1.45 
 
0.15 
 
-0.23-1.51 
Marital status 
Married 
Not married 
 
8.41(2.41) 
9.23(3.17) 
 
-0.82 
 
-1.73 
 
0.09 
 
-1.76-0.12 
Employment status 
Employed 
Unemployed 
 
8.86(2.55) 
9.11(3.40) 
 
-0.24 
 
-0.54 
 
0.59 
 
-1.12-0.63 
Total income 
<RM500 
>RM500 
 
8.97(0.27) 
9.00(2.70) 
 
-0.03 
 
-0.06 
 
0.95 
 
-1.03-0.97 
Education level 
Primary and below 
Secondary / tertiary 
 
7.92(1.52) 
9.15(3.12) 
 
-1.32 
 
-1.97 
 
0.05 
 
-2.47-0.001 
Drug and alcohol  
Yes 
No 
 
10.52(3.28) 
8.78(2.88) 
 
1.75 
 
2.58 
 
0.01* 
 
0.41-3.09 
Duration of illness 
12 years or less 
More than 12 years 
 
9.13(2.82) 
8.82(3.13) 
 
0.31 
 
0.70 
 
0.48 
 
-0.56-1.18 
Number of hospitalisations 
2 or less 
More than 2 
 
7.91(2.08) 
9.65(3.25) 
 
-1.73 
 
-3.98 
 
 
p<0.01* 
 
-2.60- -0.87 
Chlorpromazine equivalent (mg) 
≤200 mg/day 
>200 mg/day 
 
8.58(3.02) 
9.42(2.87) 
 
-0.84 
 
-1.92 
 
0.06 
 
-1.71-0.03 
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Typical antipsychotics 
Yes 
No 
 
8.03(1.73) 
9.58(3.41) 
 
-1.55 
 
-3.52 
 
p<0.01* 
 
-2.42- -0.68 
Atypical antipsychotics 
Yes 
No 
 
9.78(3.29) 
8.04(3.23) 
 
1.74 
 
4.09 
 
p<0.01* 
 
0.90-2.58 
Anticholinergic 
Yes 
No 
 
9.04(2.69) 
8.81(3.68) 
 
0.23 
 
0.45 
 
0.65 
 
-0.77-1.22 
Depot antipsychotics 
Yes 
No 
 
8.59(2.96) 
9.21(2.97) 
 
-0.62 
 
-1.37 
 
0.17 
 
-1.52-0.28 
Benzodiazepines 
Yes 
No 
 
9.38(2.50) 
8.93(3.03) 
 
0.46 
 
0.66 
 
0.51 
 
-0.91-1.82 
Antidepressants 
Yes 
No 
 
9.44(4.07) 
8.95(2.92) 
 
0.49 
 
0.48 
 
0.63 
 
-1.52-2.50 
Family history of smoking 
Yes 
No 
 
8.03(1.73) 
9.58(3.41) 
 
-1.55 
 
-3.52 
 
p<0.01* 
 
-2.42- -0.68 
Smoking status 
Smoker 
Non-smoker 
 
9.68(3.34) 
8.54(2.64) 
 
1.14 
 
2.54 
 
0.01* 
 
0.50-2.40 
Nicotine dependence 
Yes 
No 
 
10.02(3.36) 
8.72(3.20) 
 
1.30 
 
1.43 
 
0.16 
 
-0.52-3.11 
* p <0.05 
SD= standard deviation, CI = Confidence Interval 
  
 Analysis was also done to find association between the sociodemographic and 
clinical characteristics of the study participants with the positive symptoms scale.  
 As shown in the table above, several variables were found to be significantly 
associated with the positive symptoms subscale. Those participants who were male were 
associated with higher scores on the positive symptom subscale. Those with a history of 
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drug or alcohol use and with more than 2 hospitalisations to the psychiatric ward were 
also associated with higher scores. 
 Lesser positive subscale score were associated with patients taking oral typical 
antipsychotics whereas scores were higher in those taking atypical antipsychotics. Those 
with a family history of smoking were associated with lower scores. Smokers also proved 
to have statistically significant, higher scores on the positive subscale. Although it 
appeared that nicotine dependence was associated with higher positive subscale scores, 
this was not statistically significant.  
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Table 14: Multivariate analysis of PANSS positive symptoms subscale score among the 
study participants using multivariate linear regression 
*p<0.05 
CI = confidence interval 
 
 Univariate analysis found statistically significant association between the 
following variables with PANSS positive subscale scores: gender, drug and alcohol use, 
number of hospitalisations, oral typical antipsychotics, oral atypical antipsychotics, 
family history of smoking and smoking status. Performing multivariate analysis for the 
variables revealed that only number of hospitalisations was significantly associated with 
PANSS positive symptom subscale score.  
 
 Adjusted 
difference 
p 95% CI 
   
-0.65 
  
-1.67 – 0.37 Gender 0.21 
 Drug and alcohol -0.87 0.21 -2.25 – 0.50 
 Number of hospitalisations 1.46 p<0.01*  0.62 – 2.30 
 Oral typical antipsychotics 0.16 0.82 -1.27 – 1.60 
 Oral atypical antipsychotics -1.37 0.06  -2.78 – 0.02 
 Family history of smoking -0.57 0.19  -1.44 – 0.29 
 Smoking status 0.06 0.91  -1.00 – 1.13 
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4.9 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC AND CLINICAL 
CHARACTERISTICS WITH NEGATIVE SYMPTOM SUBSCALE 
Table 15: Association between sociodemographic and clinical characteristics with 
negative symptom subscale score using t-test 
 Mean (SD) Mean difference t P 95%CI 
Age    
<40 years old 
>40 years old 
 
17.95(6.29) 
16.90(5.41) 
 
1.06 
 
1.21 
 
0.23 
 
-0.66-2.77 
Gender 
Male 
Female 
 
17.30(6.08) 
65(17.54) 
 
-0.24 
 
-0.26 
 
0.79 
 
-2.03-1.55 
Ethnicity 
Malay 
Non-Malay 
 
16.48(5.93) 
18.15(5.69) 
 
-1.67 
 
-1.93 
 
0.06 
 
-3.38-0.04 
Marital status 
Married 
Not married 
 
15.59(5.12) 
18.19(5.98) 
 
-2.60 
 
-2.82 
 
0.01* 
 
-4.42-0.78 
Employment status 
Employed 
Unemployed 
 
16.44(5.08) 
18.46(6.46) 
 
-2.02 
 
-2.35 
 
0.02* 
 
-3.717-0.326 
Total income 
<RM500 
>RM500 
 
17.97(5.98) 
15.67(5.10) 
 
2.30 
 
2.33 
 
0.02* 
 
0.35-4.24 
Education level 
Primary and below 
Secondary / tertiary 
 
17.92(5.00) 
17.30(5.98) 
 
0.63 
 
0.51 
 
0.61 
 
-1.82-3.07 
 
Drug and alcohol  
Yes 
No 
 
17.81(4.05) 
17.33(6.05) 
 
0.48 
 
0.35 
 
0.73 
 
-2.20-3.16 
Duration of illness 
12 years or less 
More than 12 years 
 
17.27(5.84) 
17.51(5.87) 
 
-0.23 
 
-0.27 
 
0.79 
 
-1.95-1.48 
Number of hospitalisations 
2 or less 
More than 2 
 
16.67(5.89) 
17.84(5.79) 
 
-1.17 
 
-1.31 
 
0.53 
 
-2.92-0.59 
Chlorpromazine equivalent (mg) 
≤200 mg/day 
>200 mg/day 
 
16.67(5.97) 
18.17(5.63) 
 
-1.50 
 
-1.74 
 
0.08 
 
-3.21-0.21 
Typical antipsychotics 
Yes 
No 
 
17.29(5.94) 
17.45(5.80) 
 
-0.17 
 
-0.18 
 
0.85 
 
-1.93-1.60 
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Atypical antipsychotics 
Yes 
No 
 
17.83(5.51) 
16.87(6.20) 
 
0.96 
 
1.10 
 
0.27 
 
-0.76-2.68 
Anticholinergic 
Yes 
No 
 
17.91(5.46) 
15.94(6.64) 
 
1.97 
 
2.02 
 
0.04* 
 
0.48-3.90 
Depot antipsychotics 
Yes 
No 
 
17.71(6.22) 
17.19(5.61) 
 
0.52 
 
0.58 
 
0.56 
 
-1.25-2.29 
Benzodiazepines 
Yes 
No 
 
18.10(4.24) 
17.29(6.02) 
 
0.801 
 
0.59 
 
0.56 
 
-1.88-3.48 
Antidepressants 
Yes 
No 
 
19.56(4.42) 
17.27(5.89) 
 
2.28 
 
1.14 
 
0.25 
 
-1.66-6.22 
Family history of smoking 
Yes 
No 
 
17.25(5.69) 
17.63 
 
-0.38 
 
-0.42 
 
0.07 
 
-2.16-1.397 
Smoking status 
Smoker 
Non-smoker 
 
16.38(6.00) 
18.01(5.68) 
 
-1.63 
 
 
-1.84 
 
0.07 
 
-3.39-0.12 
Nicotine dependence 
Yes 
No 
 
16.29(6.08) 
16.61(5.92) 
 
 
-0.32 
 
 
-0.19 
 
 
0.85 
 
 
 
-3.62-2.99 
 
* p <0.05 
SD= standard deviation, CI = Confidence Interval 
 
 Independent t-test was again performed between sociodemographic and clinical 
factors and negative symptoms subscale scores of the study participants.  
 Association was found between marital status, employment status, total personal 
income and anticholinergic medication use and the PANSS negative symptoms subscale 
scores. Study participants who were not married had higher mean scores and those 
working at the time of recruitment were associated with lower mean negative symptoms 
subscale scores (16.44, SD 5.08). With regards to total monthly personal income, 
participants who earned RM500 or less in a month were associated with higher scores. 
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Those who were taking concomitant anticholinergic medication were also associated with 
higher mean negative symptoms subscale scores.  
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Table 16: Multivariate analysis of PANSS negative symptoms subscale score among the 
study participants using multiple linear regression 
 
 B p 95% CI 
   
2.19 
  
0.38 - 4.01 Marital status 0.02* 
   
1.21 
  
-0.77 - 3.21 Employment status 0.23 
   
-1.54 
  
-3.81- 0.73 Total income 0.18 
   
-1.73 
  
-3.63 – 0.17 Anticholinergics 0.08 
*p<0.05 
PANSS = Positive and Negative Syndrome Scale, CI= confidence interval 
 
After adjusting for employment status, total income and anticholinergic use, 
PANSS negative symptoms subscale score was still found to be significantly associated 
with marital status of the study participants. 
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4.10 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC AND CLINICAL 
CHARACTERISTICS WITH GENERAL PSYCHOPATHOLOGY SUBSCALE 
SCORE 
Table 17: Association between sociodemographic and clinical characteristics with general 
psychopathology subscale score using t-test 
 Mean (SD) Mean 
difference 
t P 95%CI 
Age    
<40 years old 
>40 years old 
 
24.00(5.4) 
22.54(4.9) 
 
1.46 
 
1.91 
 
0.058 
 
-0.05-2.98 
Gender 
Male 
Female 
 
23.92(5.8) 
21.95(3.2) 
 
1.97 
 
2.49 
 
0.01* 
 
0.41-3.53 
Ethnicity 
Malay 
Non-Malay 
 
23.41(5.6) 
23.05(4.7) 
 
0.36 
 
0.46 
 
0.64 
 
-1.17-1.89 
Marital status 
Married 
Not married 
 
21.64(3.9) 
23.92(5.5) 
 
-2.28 
 
 
-2.79 
 
0.01* 
 
-3.89- -0.66 
Employment status 
Employed 
Unemployed 
 
22.84(4.1) 
23.64(6.1) 
 
-0.79 
 
-1.03 
 
0.31 
 
-2.31-0.73 
Total income 
≤RM500 
>RM500 
 
23.41(5.3) 
22.65(4.6) 
 
0.76 
 
0.85 
 
0.40 
 
-0.99-2.50 
Education level 
Primary and below 
Secondary / tertiary 
 
22.54(3.5) 
23.33(5.4) 
 
-0.79 
 
-0.72 
 
0.47 
 
-2.96-1.38 
Drug and alcohol  
Yes 
No 
 
25.52(5.2) 
22.91(5.1) 
 
2.61 
 
2.20 
 
0.03* 
 
0.26-4.96 
Duration of illness 
12 years or less 
More than 12 years 
 
23.5(4.62) 
22.92(5.7) 
 
0.58 
 
0.75 
 
0.45 
 
-0.94-2.10 
Number of hospitalisations 
2 or less 
More than 2 
 
22.01(5.0) 
23.97(5.1) 
 
-1.96 
 
-2.51 
 
0.01* 
 
-3.50- -0.42 
Chlorpromazine equivalent (mg) 
≤200 mg/day 
>200 mg/day 
 
22.49(5.6) 
24.01(4.5) 
 
-1.52 
 
-1.93 
 
0.04* 
 
-3.03- -0.01 
Typical antipsychotics      
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Yes 
No 
22.29(3.78) 
23.80(5.84) 
-1.52 -1.93 0.06 -3.06-0.03 
Atypical antipsychotics 
Yes 
No 
 
24.37(5.04) 
21.86(5.04) 
 
2.51 
 
3.34 
 
p<0.01* 
 
1.03-3.40 
Anticholinergic 
Yes 
No 
 
23.89(4.57) 
21.35(6.28) 
 
2.53 
 
2.97 
 
p<0.01* 
 
0.85-4.22 
Depot antipsychotics 
Yes 
No 
 
22.99(5.99) 
22.36(4.63) 
 
-0.37 
 
-0.47 
 
0.64 
 
-1.94-1.20 
Benzodiazepines 
Yes 
No 
 
24.24(3.92) 
23.08(5.32) 
 
1.16 
 
0.96 
 
0.34 
 
-1.22-3.53 
Antidepressants 
Yes 
No 
 
25.22(6.10) 
23.11(5.13) 
 
2.11 
 
1.19 
 
0.23 
 
-1.38-5.60 
Family history of smoking 
Yes 
No 
 
23.58(5.14) 
22.60(5.23) 
 
0.98 
 
1.23 
 
0.22 
 
-0.59-2.55 
Smoking status 
Smoker 
Non-smoker 
 
24.06(6.47) 
22.70(4.14) 
 
1.36 
 
1.73 
 
0.09 
 
-0.19-2.92 
Nicotine dependence 
Yes 
No 
 
24.78(6.57) 
22.00(5.87) 
 
2.78 
 
 
1.59 
 
 
0.12 
 
 
-0.72-6.29 
 
* p <0.05 
SD= standard deviation, CI = Confidence Interval 
 
 The results from the independent t-test performed on the mentioned variables are 
shown in Table 17.  
 Males were shown to be associated with higher scores (mean 23.92, SD 5.88) on 
the general psychopathology subscale. So does being not married, taking drugs and 
alcohol and being hospitalised more than twice similarly associated. The scores were also 
higher in those participants taking higher doses of medication (mean chlorpromazine 
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equivalent dose of more than 200 mg/day), taking oral atypical antipsychotics and on 
anticholinergic medication. 
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Table 18: Multivariate analysis of PANSS general psychopathology subscale score 
among the study participants using multivariate linear regression 
*p<0.05 
CI = confidence interval 
 
 Use of oral atypical and anticholinergics was still found to be significantly 
associated with higher general psychopathology subscale scores. This could be an attempt 
on the clinician’s part to control for the symptoms present in the study participants. 
 
 Adjusted 
difference 
p 95% CI 
                               
-1.70 
1.40 
-1.44 
1.36 
1.02 
-2.21 
-1.98 
0.95 
 
-3.49 – 0.08 
-0.17 – 2.98 
-3.87 – 0.99 
-0.13 – 2.85 
-0.42 – 2.45 
-3.65 - - 0.78 
-3.61 - - 0.35 
-0.92 – 2.82 
Gender 0.06 
Marital status 0.08 
Drug and alcohol 0.24 
Number of hospitalisations 0.07 
Cpz equivalent dose 0.16 
Oral atypical antipsychotics p<0.01* 
Anticholinergics 0.02* 
Smoking status 0.31 
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4.11 CORRELATION BETWEEN TOTAL PANSS AND ITS SUBSCALE SCORE 
WITH TOTAL FTND SCORES 
Table 19: Correlation between total PANSS, positive symptoms subscale, negative 
symptoms subscale  and general psychopathology subscale scores with total FTND score. 
PANSS = Positive and Negative Syndrome Scale 
 
 Pearson correlation was used to analyse the correlation between total PANSS 
scores and each of the subscale scores with total FTND scores. However, the analysis did 
not reveal any significant correlation. 
 
 
 
 
 Total FTND score 
Total PANSS Pearson Correlation 
p 
0.07 
0.58 
Total positive symptoms score Pearson Correlation 
p 
0.13 
0.28 
Total negative symptoms score Pearson Correlation 
p 
-0.11 
0.38 
Total general psychopathology 
score 
Pearson Correlation 
p 
0.11 
0.37 
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CHAPTER 5: DISCUSSION 
 
This was a cross sectional study which was initiated to investigate the prevalence 
of nicotine dependence in an outpatient setting of a state hospital in Negeri Sembilan. It 
also served to look at other factors associated with nicotine dependence and smoking in a 
sample of patients with schizophrenia. Objective measures of disease severity were also 
used to find its association with smoking and nicotine dependence.  
 
5.1 Sociodemographic and clinical characteristics of the study participants 
This study was conducted in the outpatient psychiatric clinic of Hospital Tuanku 
Ja’afar, Seremban. The majority of the study participants were males (64.1%). This is in 
line with the National Mental Health Registry (NMHR) report which stated that in 2005, 
62% of those registered as schizophrenia were males(67).  
45.1% of the study participants were Malays, followed by Chinese (38.7%) and 
Indians (15.5%). This is actually a reflection of the general population in Malaysia, 
whereby Malays make up the majority. The NMHR report (67) also cited that in 2005, 
54% of the registered cases were Malays. 
The participants in this study were mostly single(67.4%), which was comparable 
to the 68% reported by the NMHR. The mean age of the study participants was 41 years 
old, which was higher than that recorded by the NMHR. Most of the study participants 
(45.9%) were unemployed. Schizophrenia has been well-recognised as an illness with a 
high burden of disease and disability, affecting many and more often than not in the 
reproductive years. Schizophrenia is also generally associated with substantial 
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impairments in multiple domains of life, including social adjustments and intimacy with 
others(68). 
Unemployment was found to very high in the study participants (45.9%), which is 
again, comparable to the national numbers(67). Barriers to employment in people with 
schizophrenia, among others, are clinical factors(69). Frequently cited were active 
symptoms of schizophrenia and poorer neurocognitive and intrapsychic functioning. 
74.6% of the study participants were in the low socioeconomic group, earning less than 
RM500 per month. This may be in part, due to the fact that the hospital also covers low 
income communities including those in the rural areas of Negeri Sembilan. 
The mean duration of illness of the study participants was 15 years , with a 
median of 12 years. Most of the patients had been smoking for a mean of 20 years, which 
means that most of them had started smoking before the onset of illness. Studies have 
suggested that most patients with schizophrenia who smoked started to do so before the 
illness itself(70). This suggested that there were vulnerability factors or illness-related 
factors(71) involved in those who smoke even before the onset of illness or before the 
emergence of psychotic symptom, as several studies have shown(32, 70).  
The mean number of cigarettes smoked in our sample was 17 sticks per day. Most 
epidemiological studies had defined heavy smoking as smoking more than or equal to 30 
sticks per day or 1.5 packs/day(16), which can be considered as a marker of severity of 
nicotine addiction. Several factors may contribute towards a lower mean amount of 
cigarettes smoked in our sample. Smoking cessation efforts had received a lot of attention 
over the years(72). These include the ban on tobacco company-sponsored advertisements 
and the increase in prices of cigarettes. Smoking cessation campaigns are also an ongoing 
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effort that the Malaysian government has never stopped putting money into(70). 
Furthermore, as was discussed earlier, a high number of the study participants are 
unemployed or earned less than RM500 per month. With the high price of cigarettes, they 
might not be able to buy them as much as they would like to.  
The mean and median dose of medications used by the study participants were 
lower than those reported in other studies(21, 73). However, these studies were 
conducted in the inpatient setting, which may have involved patients with more severe 
illnesses, needing higher dosages of medication to control their symptoms(21) . Our 
sample also recorded a higher number of participants on oral atypical antipsychotic 
medications. Over the years, the usage of atypical antipsychotic medication has increased, 
mostly due to the availability of generic medication, namely Risperidone(74). Admittedly, 
typical antipsychotics have limited effectiveness and tolerability(75). Therefore, a large 
proportion of patients were prescribed atypical antipsychotics early on in their treatment. 
However, studies in this area have to be weighed against the fact that higher doses of 
typical antipsychotics were used as comparators, thus making it seem that atypical 
antipsychotics were better tolerated(75). 
A high proportion of the study participants had a family history of smoking (63%). 
A subanalysis of smokers revealed that 78.3% of them had a family history of smoking, 
strengthening the hypothesis of a familial vulnerability towards smoking and 
schizophrenia. Freedman et al(76) had described a genetic neurophysiological 
abnormality in patients with schizophrenia and their relatives. This abnormality was 
temporarily corrected by high peaks of nicotine.   
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5.2  Prevalence of smoking and nicotine dependence 
The prevalence of smoking obtained in this study was 38.1%. This rate is lower 
than those found in most studies done in the Western countries. Studies done in the 
outpatient settings generally appeared to be as high as 88%(13). This rate was almost 
similar to that found in a study done in Singapore, which found a relatively high 
prevalence of smoking among Chinese patients with schizophrenia, 31.8% as compared 
to 16% in the whole Chinese population in Singapore(77). However, this study cannot be 
generalised to the population in Malaysia as it was conducted only among the Chinese 
whereas our study had a more diverse ethnic distribution. In Malaysia, the National 
Mental Health Survey conducted in 1996 estimated that 24.8% of Malaysians 
smoked(78). Therefore, the rate found in this study is still higher than those in general 
population in Malaysia. However, more recent numbers are needed to make a more valid 
comparison.  
A meta-analysis study examining association between schizophrenia and tobacco 
smoking behaviours found a prevalence of 62%(16). However, the meta-analysis 
included both studies involving in- and outpatient samples. Some reasons can be 
postulated on why the rate of smoking in our sample was found to be lower. As 
mentioned before, the Malaysian government had invested a lot in smoking cessation 
programs. The lower rates of smoking found in our sample of patients may be proof that 
there is some success to the campaigns amounted by the government. The Malaysia 
government has also used religious grounds to discourage smoking among the general 
public.  
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 The prevalence for nicotine dependence found in our study was 73.9%. Nicotine 
dependence was diagnosed  by using the Fagerstrom Test for Nicotine 
Dependence(FTND), using a cutoff point of 2(61). FTND is the most widely used 
measure for nicotine dependence. In addition, it has also been found to predict success in 
stopping smoking(57). In the large National Epidemiological Survey on Alcohol and 
Related Conditions (NESARC)(24), it was found that nicotine dependence associated 
with cigarette use constituted 93.7% of all nicotine dependence. However, the survey did 
not examine the association between nicotine dependence and psychotic disorders. A 
study done on psychiatric inpatients found that 47.5% of them with the diagnosis of 
psychotic disorder were nicotine-dependent(29). Our study found a higher percentage. 
This could be because the other study used a cutoff point of 6 for the FTND. It also 
studied inpatients and sampled them just before their discharge from the hospital, where 
access to cigarettes was limited. All this could have artificially lowered the rates found. 
The mean total FTND score found in our study was 4.16. This was expected as other 
studies which recorded higher scores were done in Western countries with higher 
smoking prevalences.  
 
 Our study found a smoking cessation rate of 8.8%. However, no data is available 
regarding smoking cessation rates in the general population in Malaysia. Western studies 
have quoted low cessation rates when compared with general population(16). Our study 
did not explore motivation to quit smoking in our sample of participants. However, 
studies have reported that higher readiness to change or motivation to quit smoking have 
been associated with success with quitting and more worries with regards to negative 
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consequences of smoking(79). It was also found that 79% of smokers in an outpatient 
psychiatric treatment were in the precontemplation stage and were not considering 
change(80).  
 
5.3 Smoking and nicotine dependence in patients with schizophrenia : associated 
factors 
The finding that being male is associated with smoking is in line with other 
previous studies done, which also showed a greater preponderance for smoking in men as 
compared to women(16, 81). Univariate analysis found several other factors to be 
significantly associated with smoking status in patients with schizophrenia. When 
controlled for these other (sociodemographic) factors, age, gender, ethnicity and drug and 
alcohol use was still found to be associated with smoking status. However, this did not 
replicate the results of other studies which did not show any significant differences 
between smokers and non-smokers in the sample of patients in terms of demographic 
variables(28). This could be due to the fact that in Malaysia, the ethnic distribution is 
more diverse, with the Malays making up the main bulk of it. In studies done in other 
countries, not much consideration was taken with regards to the ethnicity of their study 
subjects. In the United States, younger adults who daily had the highest risk of becoming 
dependent(23). In our sample, those less than 40 years old were found to be more likely 
to smoke. Efforts should be focused on this age group to reduce the morbidity associated 
with nicotine dependence. Furthermore, it has also been shown that those who stop 
smoking before reaching middle age can avoid more than 90% of the mortality associated 
with lung cancer which is attributed to nicotine(82).    
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After including all clinical variables found statistically significant in the 
univariate analysis into the logistics regression analysis, male gender, being Malay, 
having a total income of more than RM500 and the use and drug and alcohol was still 
found to be significantly associated with smoking. Due to the high costs of maintaining 
the smoking habit, it was more likely that our participants had to earn more. Cigarette 
smoking may be a representation of substance use behaviour with a greater 
preponderance for the major psychiatric diagnoses(83), thus the finding that the use of 
drugs and alcohol was significantly associated with smoking.  
Other studies have also shown, as in this study, that there were no significant 
differences between smokers and non-smokers with regards to typical and atypical 
antipsychotic dosage or in those receiving anticholinergic medication(28). The same 
study found that patients with schizophrenia who were current smokers were more likely 
to have been ill longer and had higher number of hospitalisations. This was not found in 
our study and even though the smokers in our sample appeared to have more 
hospitalisations, it was not statistically significant. Compared to the study by Patkar et 
al(28), our study participants were ill for a mean of 14.99 years and hospitalized 1.73 
times as opposed to 20.3 years of being ill and hospitalized 6.3 times in the other study. 
This could explain the difference in the results of the study. However, it was shown with 
statistical significance that patients who had been ill for more than 12 years scored higher 
on the FTND.  
In terms of nicotine dependence, no significant association was found between the 
nicotine-dependent and non-dependent smokers with regards to sociodemographic, 
treatment variables, number of hospitalisations, drug and alcohol use or family history of 
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smoking. This was also found in another study conducted by Aguilar et al(84). This 
suggested that nicotine dependence cannot be accounted for by the afore-mentioned 
factors.   
 
5.4 Smoking and nicotine dependence in patients with schizophrenia : disease 
severity 
 PANSS has been commonly used to measure severity of symptoms in patients 
with schizophrenia. Smoking has been associated with self-medication of symptoms. 
Various studies done regarding this have found different results. Goff et al(17) found 
higher levels of positive and negative symptoms via analysis of subscales of the Brief 
Psychiatric Rating Scale (BPRS). Other studies have also found no difference in PANSS 
score between smokers and non-smokers(34, 81).  Our study found that the total positive 
and total general psychopathology scores were significantly associated with nicotine 
dependence. This somewhat supported the hypothesis that patients with positive 
symptoms self-medicate themselves to reduce these symptoms. This could also explain 
the higher scores associated with general psychopathology. We found that smokers had 
lower scores on the negative subscale of PANSS. This was also found in another study 
done by Ziedonis et al(20). However, it was found to be not significant. The reasons for 
this could be two-fold : patients are using nicotine to treat their symptoms or nicotine use 
had modified the clinical presentation by worsening the negative symptoms. 
 The significance of these two variables were not found in the multivariate analysis. 
So were univariate analyses done between nicotine dependence and the various 
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sociodemographic, clinical and other illness-related variables. However, this does not 
refute the self-medication hypothesis.  
 
5.5 Correlation between nicotine dependence and illness severity 
 Correlation analysis performed between FTND scores with PANSS total and 
subscale scores did not reveal any significant association. The study done by Patkar et 
al(28), however, found significant positive correlations between Fagerstrom scores with 
PANSS total negative symptom scores but not with the positive symptoms subscale 
scores. The study done by Patkar et al, however, was conducted in a locked psychiatric 
inpatient unit which served a predominantly inner-city population. Their sample was 
composed mostly of patients recently admitted to the hospital. Our study, on the other 
hand, was done in the outpatient psychiatric unit in a state hospital which serves a 
heterogenous population. Non-significance can also imply that a bigger study might 
detect difference between these scores. 
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CHAPTER 6: LIMITATIONS AND STRENGTHS 
 
The author has identified several limitations of the study: 
1. The final sample size of this study did not reach the targeted number, which was 
calculated as 250 participants. Due to the limited resources available, the 
researcher did not manage to achieve the targeted sample size. The study involved 
only a single researcher and the psychiatric outpatient follow-up clinic in Hospital 
Tuanku Ja’afar, Seremban only ran twice a week. In the future, similar studies 
would need bigger sample sizes in order to increase the power of the studies. A 
bigger study would also reduce the chances of a significant finding happening by 
chance. 
2. This study only involved a single site. A multi-centre study would reveal a more 
generalisable result reflecting the true population of patients with schizophrenia. 
3. This was a cross-sectional study, which could only reveal associations between 
smoking and nicotine dependence with sociodemographic, clinical and other 
illness-related variables. It cannot suggest cause-effect relationships between the 
variables. 
4. Some of the information obtained from the patients cannot be verified as there 
was no accompanying guardian. This could, therefore, lead to information bias. 
5. Information such as duration of illness may be subject to recall bias. Information 
the participants’ case notes might also not be adequate to confirm the information 
obtained from the participants. 
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6. Further measures related to the illness were not taken into account , for example 
co-morbid anxiety and depression or the presence of extrapyramidal symptoms.  
7. Our study did not take into account other variables which might act as 
confounders to nicotine dependence. Examples of these are the different kings of 
medication that a patient might be on.  
  
Some identified strengths of the study include : 
1. This study can be considered the first study in Malaysia on specifically smoking 
and nicotine dependence in patients with schizophrenia. It has also opened up new 
grounds to initiate other studies pertaining to nicotine dependence. Nicotine 
dependence is a very wide subject which can fuel many more studies in the future. 
This study can serve as a reference point for future studies in smoking and 
nicotine dependence in patients with schizophrenia. 
2. This study compared patients with schizophrenia who smoked and didn’t smoke. 
3. The study utilised validated and objective measure including the M.I.N.I and the 
Fagerstrom Test for Nicotine Dependence (FTND). In this study, most 
participants had been given the Malay version of FTND, which has also been 
validated(61). 
4. This study was done in the outpatient setting which would constitute a true 
measure of current smoking. In comparison, inpatient settings would not give a 
true picture of current smoking behaviour due to the ban on smoking in all the 
hospitals in Malaysia. 
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5. The researcher used a handheld device as a way to check for current smoking 
status. The carbon monoxide monitor can give a general idea of whether the study 
participants were actual smokers or not. 
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CHAPTER 7: CONCLUSION AND RECOMMENDATIONS 
As a substance which is most commonly used by patients with schizophrenia, its 
effects on this group of patients need to be recognized as nicotine can also modify the 
clinical presentation and manifestations of the illness itself. In addition, the increased 
morbidity and mortality which is associated with nicotine use in patients with 
schizophrenia cannot be overemphasized. 
This study has managed to obtain the objectives which were set out for it. This 
was a form of pilot study which found a prevalence of 38.1% of smokers in a sample of 
181 patients with schizophrenia in an outpatient population in the state hospital of 
Seremban, Negeri Sembilan. In addition to that, we also found a smoking cessation rate 
of 8.8%. 
Nicotine dependence has been a focus of attention in recent years. Nicotine 
dependence, diagnosed using the Fagerstrom Test for Nicotine Dependence (FTND) was 
found in 73.9% of the smokers who completed the FTND.  
Smoking was found to be associated with being male, Malay, earning more than 
RM500 per month and with the use of drugs and alcohol. Nicotine dependence, on the 
other hand, cannot be explained by sociodemographic factors, clinical characteristics or 
measures of disease severity which we included in our study. We also did not find any 
correlation between nicotine dependence and disease severity. 
Future studies in the field should attempt to recruit more patients into their study 
and involve more than one site. It is also recommended to utilize longitudinal study 
designs that could better establish the cause and effect between nicotine dependence and 
the many factors that are associated with it. More measures should also be included to 
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provide objective assessments of illness or medication related issues such as the 
extrapyramidal symptoms or other tests of cognition.  
Other co-morbidities such as depression and anxiety should also be addressed. 
Higher nicotine dependence have been observed in depressed as compared to non-
depressed smokers(24, 85). The association between nicotine dependence and depression 
and  anxiety can also be seen in successful quitters whereby they are less likely to have a 
lifetime diagnosis of depression and anxiety(86).  
It is evident that  smoking and nicotine dependence in patients with schizophrenia 
is fraught with many associated factors which need more exploration . This study had 
shown that smoking and nicotine dependence are undoubtedly important issues which 
need to be considered and included into the management of patients with schizophrenia 
 It can be concluded that nicotine dependence is the most common dual diagnosis 
in patients with schizophrenia. Withdrawal from nicotine can exacerbate symptoms in 
patients with schizophrenia. Therefore, smoking cessation programs are important to 
address issues that may arise and complicate the clinical picture of a patient with 
schizophrenia.  
 The focus of smoking cessation in patients with schizophrenia should be on 
coping skills for negative affect, boredom and handling of situations identified as high 
risk in addition to education, medication or replacement therapy(87). Instead of 
addressing motivation to change, an area that needs more attention in smokers with 
schizophrenia  is their low self-efficacy for quitting. 
 Patients should be made aware and assured of not just the physical and medical 
benefits of smoking cessation but also of the psychological well-being that they will 
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experience. Studies have shown that smokers who have stopped for 6 months 
experienced a decline in psychological problems(88). There were also reports of reduced 
anxiety levels after quitting, with enduring mood improvements(89) and increased self-
esteem(90). 
 The introduction of smoke-free policies in the mental health settings need co-
ordination between inpatient, outpatient and smoking cessation services(91, 92). 
Specialist services with regards to smokers with mental illness have recorded abstinence 
rates as high as those in the general population(93). If more active interventions were to 
be taken in the mental health settings, it is only logical that nicotine dependence should 
be considered a chronic illness(94). 
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